

Supplemental Online Content

Lazarus JV, Agirre-Garrido L, Díaz LA, et al. Cost-effectiveness of MASH diagnosis and management approaches among those with type 2 diabetes. *JAMA Netw Open*. 2025;8(11):e2542750. doi:10.1001/jamanetworkopen.2025.42750

eTable 1. Management approaches with corresponding health care level(s) for action to prevent, detect, and treat MASH and liver fibrosis among adults aged 19 and above living with T2D

eTable 2. Transition probabilities matrix for Brazil

eFigure 1. Markov state-transition model showing the ten health states for Brazil

eTable 3. Transition probabilities matrix for Chile

eFigure 2. Markov state-transition model showing the ten health states for Chile

eTable 4. Transition probabilities matrix for Germany

eFigure 3. Markov state-transition model showing the ten health states for Germany

eTable 5. Transition probabilities matrix for Italy

eFigure 4. Markov state-transition model showing the ten health states for Italy

eTable 6. Transition probabilities matrix for Japan

eFigure 5. Markov state-transition model showing the ten health states for Japan

eTable 7. Transition probabilities matrix for Saudi Arabia

eFigure 6. Markov state-transition model showing the ten health states for Saudi Arabia

eTable 8. Transition probabilities matrix for South Africa

eFigure 7. Markov state-transition model showing the ten health states for South Africa

eTable 9. Transition probabilities matrix for Spain

eFigure 8. Markov state-transition model showing the ten health states for Spain

eTable 10. Transition probabilities matrix for Sweden

eFigure 9. Markov state-transition model showing the ten health states for Sweden

eTable 11. Transition probabilities matrix for Tanzania

eFigure 10. Markov state-transition model showing the ten health states for Tanzania

eTable 12. Transition probabilities matrix for Thailand

eFigure 11. Markov state-transition model showing the ten health states for Thailand

eTable 13. Transition probabilities matrix for United States

eFigure 12. Markov state-transition model showing the ten health states for United States

eTable 14. Estimated cost of each fibrosis stage (adjusted for inflation, 2023 international \$) per country

eTable 15. Cost of each management approach (MA) in international dollars for 2023

eTable 16. QALYs used in the analysis for each country and their literature sources

eTable 17. Highly cost-effective thresholds for all management approaches per country

eTable 18. Total costs and QALYs in AFR for both the ELF and VCTE arms

eTable 19. Total costs and QALYs in AMR for both the ELF and VCTE arms

eTable 20. Total costs and QALYs in SEAR for both the ELF and VCTE arms

eTable 21. Total costs and QALYs in EUR for both the ELF and VCTE arms

eTable 22. Total costs and QALYs in EMR for both the ELF and VCTE arms

eTable 23. Total costs and QALYs in WPR for both the ELF and VCTE arm

eFigure 13. Expansion path for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)

eFigure 14. Expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)

eFigure 15. Expansion path for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)

eFigure 16. Expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)

eFigure 17. Expansion path for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand) and WPR (Japan)

eFigure 18. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)

eFigure 19. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)

eFigure 20. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)

eFigure 21. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)

eFigure 22. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand) and WPR (Japan)

eTable 24. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for AFR for both ELF (left column) and VCTE (right column) arms

eTable 25. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms

eTable 26. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for EMR for both ELF (left column) and VCTE (right column) arms

eTable 27. Probabilistic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms

eTable 28. Probabilistic sensitivity analysis: total costs, QALYs, and ACERs for SEAR for both ELF (left column) and VCTE (right column) arms

eTable 29. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for AFR for both ELF (left column) and VCTE (right column) arms

eTable 30. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms

eTable 31. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for EMR for both ELF (left column) and VCTE (right column) arms

eTable 32. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms

eTable 33. Deterministic sensitivity analysis: Total costs, QALYs, and ACER for WPR for both ELF (left column) and VCTE (right column) arms

eFigure 23. Deterministic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)

eFigure 24. Deterministic sensitivity analysis (built through ICERs): expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)

eFigure 25. Deterministic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)

eFigure 26. Deterministic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)

eFigure 27. Deterministic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand)

eReferences.

This supplemental material has been provided by the authors to give readers additional information about their work.

1. Management approaches

eTable 1. Management approaches with corresponding health care level(s) for action to prevent, detect, and treat MASH and liver fibrosis among adults aged 19 and above living with T2D

Management approaches (N = 14)	Healthcare level(s) for action
0: SoC	Primary, secondary, and tertiary (not implemented systematically)
1: FIB-4 screening	Primary
2A: FIB-4 and ELF screening	Primary and secondary
2B: FIB-4 and VCTE screening	
3A: FIB-4 and ELF screening, a hepatologist consult, and ILIs prescription	
3B: FIB-4 and VCTE screening, a hepatologist consult, and ILIs prescription	
4A: FIB-4 and ELF screening, a hepatologist consult, and resmetirom prescription	
4B: FIB-4 and VCTE screening, a hepatologist consult, and resmetirom prescription	
5A: FIB-4 and ELF screening, a hepatologist consult, and resmetirom and ILIs prescription	
5B: FIB-4 and VCTE screening, a hepatologist consult, and resmetirom and ILIs prescription	
6A: FIB-4 and ELF screening, a hepatologist consult, and semaglutide prescription	
6B: FIB-4 and VCTE screening, a hepatologist consult, and semaglutide prescription	
7A: FIB-4 and ELF screening, a hepatologist consult, and semaglutide and ILIs prescription	
7B: FIB-4 and VCTE screening, a hepatologist consult, and semaglutide and ILIs prescription	

Abbreviations: ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; ILI, intensive lifestyle intervention; VCTE, vibration-controlled transient elastography.

2. Transition probabilities:


2.1. Transition probabilities used for all 12 countries:

Transition probabilities were obtained from the literature from each country. These transition probabilities were not available for all of the countries; for Brazil, Chile and Saudi Arabia, the transition probabilities from the United States were used. For South Africa and Tanzania, some of the transition probabilities from Spain were used. For Thailand, some of the transition probabilities were from China (from Estes C *et al*) were used (see the references in each transition probability matrix).

eTable S2. Transition probabilities matrix for Brazil ¹⁻³

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9426	0.0164								0.0410
F1		0.8591	0.0999							0.0410
F2			0.8591	0.0999						0.0410
F3				0.8780	0.0810					0.0410
F4				0.0538	0.6445	0.0767	0.0900			0.1350
DC						0.7171	0.0072	0.0071		0.2686
HCC							0.6000	0.1500		0.2500
LT								0.0570	0.7900	0.1530
LT1Y									0.8400	0.1600
F0										1.0000

eFigure 1. Markov state-transition model showing the ten health states for Brazil




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 3. Transition probabilities matrix for Chile ^{1,2,4}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9426	0.0164								0.0410
F1		0.8591	0.0999							0.0410
F2			0.8591	0.0999						0.0410
F3				0.8780	0.0810					0.0410
F4				0.0538	0.6445	0.0767	0.0900			0.1350
DC						0.7171	0.0072	0.0071		0.2686
HCC							0.6000	0.1500		0.2500
LT								0.0200	0.8400	0.1400
LT1Y									0.8400	0.1600
F0										1.0000

eFigure 2. Markov state-transition model showing the ten health states for Chile




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 4. Transition probabilities matrix for Germany ^{1,5-7}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9488	0.0112								0.0400
F1		0.8741	0.0859							0.0400
F2			0.8741	0.0859						0.0400
F3				0.8907	0.0693					0.0400
F4					0.9070	0.0390	0.0140			0.0400
DC						0.8260	0.0140	0.0310		0.1290
HCC							0.3950	0.1780		0.4270
LT								0.100	0.79	0.11
LT1Y									0.8	0.200
F0										1.0000

eFigure 3. Markov state-transition model showing the ten health states for Germany




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 5. Transition probabilities matrix for Italy ^{1,8}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9598	0.0102								0.0300
F1		0.8743	0.0957							0.0300
F2			0.8743	0.0957						0.0300
F3				0.8655	0.0645					0.0700
F4				0.0400	0.7800	0.1000	0.0100			0.0700
DC						0.5400	0.0300	0.1100		0.3200
HCC							0.4800	0.1500		0.3700
LT								0.0320	0.9110	0.0570
LT1Y									0.8800	0.1200
F0										1.0000

eFigure 4. Markov state-transition model showing the ten health states for Italy




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 6. Transition probabilities matrix for Japan ^{1,9–12}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.8882	0.0690					0.0028			0.0400
F1		0.8671	0.0626			0.0275	0.0028			0.0400
F2			0.8671	0.0626		0.0275	0.0028			0.0400
F3				0.8598	0.0424	0.0550	0.0028			0.0400
F4					0.4724	0.4400	0.0276			0.0600
DC						0.7900	0.0300	0.1000		0.0800
HCC							0.5339	0.3180		0.1481
LT								0.0000	0.8180	0.1820
LT1Y								0.0000	0.8500	0.1500
F0										1.0000

eFigure 5. Markov state-transition model showing the ten health states for Japan




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 7. Transition probabilities matrix for Saudi Arabia ^{2,13}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9426	0.0164								0.0410
F1		0.8591	0.0999							0.0410
F2			0.8591	0.0999						0.0410
F3				0.8780	0.0810					0.0410
F4				0.0538	0.6445	0.0767	0.0900			0.1350
DC						0.7171	0.0072	0.0071		0.2686
HCC							0.6000	0.1500		0.2500
LT									0.9015	0.0985
LT1Y									0.964	0.036
F0										1.0000

eFigure 6. Markov state-transition model showing the ten health states for Saudi Arabia




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 8. Transition probabilities matrix for South Africa ^{13–15}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9493	0.0107								0.0400
F1		0.8596	0.1004							0.0400
F2		0.0000	0.8596	0.1004						0.0400
F3				0.8923	0.0677					0.0400
F4					0.8850	0.0400	0.015			0.0600
DC						0.7710	0.0680	0.023		0.1380
HCC							0.5300	0.0400		0.4300
LT									0.7500	0.2500
LT1Y									0.7400	0.2600
F0										1.0000

eFigure 7. Markov state-transition model showing the ten health states for South Africa




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 9. Transition probabilities matrix for Spain ^{1,14,16}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9493	0.0107								0.0400
F1		0.8596	0.1004							0.0400
F2			0.8596	0.1004						0.0400
F3				0.8923	0.0677					0.0400
F4					0.8850	0.0400	0.0150			0.0600
DC						0.7710	0.0680	0.0230		0.1380
HCC							0.5300	0.0400		0.4300
LT									0.874	0.126
LT1Y									0.8050	0.1950
F0										1.0000

eFigure 8. Markov state-transition model showing the ten health states for Spain




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 10. Transition probabilities matrix for Sweden ^{17–19}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.8277	0.0500	0.0030	0.0070	0.0020		0.0003			0.1100
F1		0.8190	0.0530	0.0120	0.0020		0.0040			0.1100
F2		0.0380	0.7920	0.0450	0.0110		0.0040			0.1100
F3		0.0150	0.0620	0.7637	0.0440		0.0053			0.1100
F4				0.0460	0.7700	0.0600	0.0140			0.1100
DC						0.5300	0.2600	0.0080		0.2020
HCC							0.6500	0.1500		0.2000
LT									0.978	0.022
LT1Y									0.946	0.054
F0										1.0000

eFigure 9. Markov state-transition model showing the ten health states for Sweden




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 11. Transition probabilities matrix for Tanzania ^{13–15}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9493	0.0107								0.0400
F1		0.8596	0.1004							0.0400
F2		0.0000	0.8596	0.1004						0.0400
F3				0.8923	0.0677					0.0400
F4					0.8850	0.0400	0.015			0.0600
DC						0.7710	0.0680	0.023		0.1380
HCC							0.5300	0.0400		0.4300
LT									0.7500	0.2500
LT1Y									0.7400	0.2600
F0										1.0000

eFigure 10. Markov state-transition model showing the ten health states for Tanzania




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 12. Transition probabilities matrix for Thailand ^{13,20}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9526	0.0074					0.0000			0.0400
F1		0.8934	0.0666				0.0000			0.0400
F2			0.8934	0.0666			0.0001			0.0400
F3				0.9150	0.0449		0.0001			0.0400
F4					0.7570	0.0371	0.0059			0.2000
DC						0.3597	0.0300	0.0003		0.6100
HCC							0.3884	0.0016		0.6100
LT								0.1348	0.7999	0.0653
LT1Y									0.9347	0.0653
F0										1.0000

eFigure 11. Markov state-transition model showing the ten health states for Thailand




Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

eTable 13. Transition probabilities matrix for United States ^{1,2}

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
F0	0.9426	0.0164								0.0410
F1		0.8591	0.0999							0.0410
F2			0.8591	0.0999						0.0410
F3				0.8780	0.0810					0.0410
F4				0.0538	0.6445	0.0767	0.0900			0.1350
DC						0.7171	0.0072	0.0071		0.2686
HCC							0.6000	0.1500		0.2500
LT									0.9015	0.0985
LT1Y									0.964	0.036
F0										1.0000

eFigure 12. Markov state-transition model showing the ten health states for United States



Abbreviations: D, death; DC, decompensated cirrhosis; F0, metabolic dysfunction-associated steatohepatitis with no fibrosis (fibrosis stage 0); F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4; HCC, hepatocellular carcinoma; LT, liver transplant; LT1Y, liver transplant after one year.

3. Cost data:

Cost data was obtained from each country's fee schedules, literature, or expert opinion²¹⁻⁶².

3.1. Definition for each cost stage and cost of fibrosis stage in the 12 countries

To estimate the cost of each fibrosis stage, these definitions were built.

F0-F1: This cost was associated with the routine primary health care doctor visit and a regular blood test, which was included as the cost of a FIB-4 test with a low-risk result, which would not require any additional specialist doctor consultation.

The cost variables included including health workers and lab tests costs:

- Primary health care follow-up visit
- Blood sample collection
- Complete Blood Count (CBC)
- Liver function test (aspartate transferase (AST), alanine transaminase (ALT) included)
- Lipid profile (complete cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), very low-density lipoprotein VLDL)
- Hemoglobin A1c (HbA1c)

F2-F3: The cost of this fibrosis stage would include the cost of additional tests (VCTE/ELF) and specialist doctors follow-up.

Here are the variables included to estimate the cost of these fibrosis stages:

- Specialist doctor baseline visit (hepatology)
- VCTE/ELF

F4: For this fibrosis stage, we included the cost of screening for decompensated cirrhosis and HCC according to what is reported for the public health system.

- Lab tests: liver function test.
- Specialist doctor visit follow-up.
- AFP
- Echography

DCC: Hospitalization cost reported by the health care fee schedules, based on the severity wage and the cost reported in the public budget.

LT: Hospitalisation cost reported by the health care system for the liver transplantation, based on the severity wage used by the system and the cost reported in the public budget. Additionally, as this cost was reported based on four severity stages, the mean will be provided.

LT1Y: cost of care after 1 year transplant. As reported in the literature, not in fee schedules.

In Table S14, the cost of all the fibrosis stages were reported, based on the previous definitions and with the original data obtained from public prices on fee schedules, the literature if needed and estimates and assumptions made and validated by the co-authors.

eTable 14. Estimated cost of each fibrosis stage (adjusted for inflation, 2023 international \$) per country

	Brazil	Chile	Germany	Italy	Japan	Saudi Arabia	South Africa	Spain	Sweden	Tanzania	Thailand	United States
F0-ELF	43.70	82.84	70.94	78.83	69.60	487.31	146.20	272.67	2,031.51	90.85	123.68	183.74
F0-VC TE	43.70	82.84	70.94	78.83	69.60	487.31	146.20	272.67	2,031.51	90.85	123.68	183.74
F1-ELF	43.70	82.84	70.94	78.83	69.60	487.31	146.20	272.67	2,031.51	90.85	123.68	183.74
F1-VC TE	43.70	82.84	70.94	78.83	69.60	487.31	146.20	272.67	2,031.51	90.85	123.68	183.74
F2-ELF	145.05	198.49	139.48	216.67	52.18	313.35	240.48	506.24	1,187.74	234.22	265.68	302.19
F2-VC TE	80.74	457.35	446.91	208.43	52.81	172.59	407.69	497.26	2,137.49	398.47	277.11	278.63
F3-ELF	145.05	198.49	139.48	216.67	52.18	313.35	240.48	506.24	1,187.74	234.22	265.68	302.19
F3-VC TE	80.74	457.35	446.91	208.43	52.81	172.59	407.69	497.26	2,137.49	398.47	277.11	278.63
F4-ELF	1,384.43	3,585.98	2,352.44	6,688.33	2,681.56	1,573.60	2,891.08	8,223.95	9,149.24	199.45	6,643.20	6,746.91
F4-VC TE	1,384.43	3,585.98	2,352.44	6,688.33	2,681.56	1,573.60	2,891.08	8,223.95	9,149.24	199.45	6,643.20	6,746.91
DC C	1,488.26	9,833.68	11,481.19	11,045.00	2,679.97	9,441.62	9,235.38	23,581.85	15,651.59	693.76	12,339.78	26,397.09
HCC	6,488.77	16,325.17	10,388.75	21,493.33	16,325.55	60,798.48	2,868.13	21,690.14	12,395.42	206.48	14,954.00	26,076.49
LT	28,205.36	159,936.95	313,890.70	122,956.67	31,854.67	458,121.83	137,362.64	166,908.23	127,030.55	82,417.58	56,285.18	172,288.96
LT1Y	14,102.68	79,968.48	60,000.00	2,365.00	15,927.33	229,060.91	68,681.32	83,454.11	63,515.28	41,208.79	28,142.59	70,088.51

Abbreviations: F0, fibrosis stage 0; F1, fibrosis stage 1; F2, fibrosis stage 2; F3, fibrosis stage 3; F4, fibrosis stage 4 or compensated cirrhosis; DCC, Decompensated cirrhosis; HCC, Hepatocellular carcinoma; LT, Liver transplant; LT1Y, liver transplant after 1st year.

3.2. Definitions for each of the 14 management approaches and the cost in the 12 countries

Fourteen management approaches were proposed in order to assess them. The unit cost for each approach was made based on the following management approaches, set out below. For the cost of each fibrosis stage, the cost for each item was sourced from the fee schedules of the health system(s) of each country, from the literature if not available in previous publications. All estimations and assumptions made were validated by the relevant experts.

Management approach 1: FIB-4 Test

The defined care pathway for this management approach was screening through a FIB-4 Test at the primary health care level among people with T2D as a systematic measure in each primary health care consultation for routine T2D control. The costs included for this approach were the cost of a baseline and follow-up visit with the general practitioner, a visit with a nurse practitioner for the blood sample collection (in some countries the blood extraction is done by a laboratory technician or other technical personnel), the cost of the routine blood tests (complete blood count, lipid profiles, liver function test and HbA1c).

Management approach 2: FIB-4 + ELF/VCTE

This management approach started with a FIB-4 test and an additional confirmatory test: Enhanced Liver Fibrosis (ELF) and the vibration-controlled transient elastography (VCTE).

Involves the same tests and visit costs as in management approach 1 but additional cost of ELF test or VCTE was added, including the cost of a specialist consultations within a hepatologist.

Management approach 3: FIB-4 + ELF/VCTE + HEP + ILIs

Expanded upon the previous intervention by adding hepatologist follow-up visits (baseline and follow-up consultation) and the cost of intensive lifestyle interventions (ILIs), which typically focus on weight loss, diet, and physical activity to manage liver conditions for one year.

Management approach 4: FIB-4 + ELF/VCTE + HEP + RES

Added the MASH treatment with annual cost of resmetirom, a pharmacological treatment, to management approach 2.

Management approach 5: FIB-4 + ELF/VCTE + HEP + RES + ILIs

In this approach, the combination of the pharmacological treatment of resmetirom, alongside ILIs were combined. The cost of resmetirom, was the current cost in the US and the 80% of the price in the rest of the countries

Management approach 6: FIB-4 + ELF/VCTE + HEP + SEM

This management approach added pharmacological treatment with semaglutide (annual cost) to management approach 2.

Management approach 7: FIB-4 + ELF/VCTE + HEP + SEM + ILIs

This last management approach, combines semaglutide treatment with ILIs.

eTable 15. Cost of each management approach (MA) in international dollars for 2023

MA	Brazil		Chile		Germany		Italy		Japan		Saudi Arabia	
	A	B	A	B	A	B	A	B	A	B	A	B
1	41	41	109	109	76	76	106	106	78	78	716	716
2	186	122	307	566	223	530	323	314	130	130	1,029	888
3	3,111	3,047	3,251	3,510	3,206	3,514	3,271	3,263	3,077	3,078	4,001	3,860
4	38,270	38,206	38,409	38,668	63,772	64,080	38,430	38,421	38,236	38,237	39,160	39,019
5	41,191	41,127	41,331	41,590	66,694	67,001	41,351	41,343	41,157	41,158	42,081	41,940
6	2,050	1,986	2,176	2,435	1,579	1,886	1,238	1,230	496	497	5,020	4,879
7	4,971	4,907	5,098	5,356	4,500	4,808	4,159	4,151	3,418	3,418	7,941	7,800

A: Screening through Enhanced Liver Fibrosis (ELF) test; B: Screening though Vibration Controlled Transient Elastography (VCTE).

eTable 15. Cost of each management approach (MA) in international dollars for 2023 (continued)

MA	South Africa		Spain		Sweden		Tanzania		Thailand		United States	
	A	B	A	B	A	B	A	B	A	B	A	B
1	190	190	411	411	1,309	1,309	94	94	176	176	184	184
2	431	598	917	908	2,496	3,446	328	492	442	453	608	462
3	3,416	3,584	3,931	3,922	6,486	7,436	3,304	3,469	4,317	4,329	5,438	5,291
4	39,089	38,678	39,089	39,081	41,645	42,595	38,463	38,627	39,476	39,487	48,383	48,237
5	41,496	41,664	42,011	42,002	44,566	45,516	41,384	41,549	42,397	42,409	53,038	52,891
6	5,770	5,937	2,219	2,210	9,482	10,432	16,075	16,239	8,573	8,584	5,073	4,927
7	8,691	8,858	5,141	5,132	12,403	13,353	18,996	19,161	8,573	8,584	9,728	9,582

A: Screening through Enhanced Liver Fibrosis (ELF) test; B: Screening through Vibration Controlled Transient Elastography (VCTE).

4. Utility values: Quality adjusted life year (QALYs)

eTable 16. QALYs used in the analysis for each country and their literature sources

	F0	F1	F2	F3	F4	DC	HCC	LT	LT1Y	D
Brazil ⁶³	0.850	0.850	0.850	0.790	0.780	0.650	0.250	0.500	0.700	0.000
Chile ⁶³	0.850	0.850	0.850	0.790	0.780	0.650	0.250	0.500	0.700	0.000
Germany	0.830	0.830	0.760	0.760	0.740	0.720	0.720	0.790	0.790	0.000
Italy ⁶⁸	0.730	0.730	0.730	0.730	0.710	0.570	0.496	0.567	0.576	0.000
Japan ⁶⁹	0.854	0.854	0.854	0.854	0.737	0.671	0.675	0.700	0.700	0.000
Saudi Arabia ²	0.900	0.840	0.840	0.835	0.807	0.620	0.620	0.620	0.840	0.000
South Africa ¹⁴	0.930	0.930	0.920	0.790	0.760	0.690	0.670	0.500	0.770	0.000
Spain ¹⁴	0.930	0.930	0.920	0.790	0.760	0.690	0.670	0.500	0.770	0.000
Sweden ¹⁷	0.910	0.865	0.794	0.759	0.630	0.561	0.533	0.572	0.605	0.000
Tanzania ¹⁴	0.930	0.930	0.920	0.790	0.760	0.690	0.670	0.500	0.770	0.000
Thailand ^{65,66}	0.890	0.855	0.819	0.784	0.748	0.672	0.380	0.765	0.832	0.000
United States ²	0.900	0.840	0.840	0.835	0.807	0.620	0.620	0.620	0.840	0.000

5. Cost-effective thresholds

eTable 17. Highly cost-effective thresholds for all management approaches per country

Country	GDP per capita (In purchasing power parity (constant 2023 international \$))
Brazil	18,554
Chile	29,507
Germany	61,909
Italy	52,700
Japan	46,268
Saudi Arabia	49,568
South Africa	14,284
Spain	46,357
Sweden	64,191
Tanzania	3,581
Thailand	21,113
United States	73,637

Source: World Bank⁶⁷

6. Supplementary results

eTable 18. Total costs and QALYs in AFR for both the ELF and VCTE arms

South Africa - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	3,458,666,354	23,914,376	5,533,864,357	38,262,989	6,571,466,375	45,437,316	0: Standard of care	3,614,086,515	23,914,376	5,782,536,533	38,262,989	6,866,764,694	45,437,316
2A: FIB-4 + ELF	4,107,204,678	24,289,461	6,571,525,336	38,863,124	7,803,689,247	46,149,978	1: FIB-4 Only	3,930,350,975	24,045,560	6,288,559,504	38,472,884	7,467,667,196	45,686,567
3A: FIB-4 + ELF + Hep + ILI	56,768,847,032	24,974,249	90,830,125,547	39,958,786	107,860,814,311	47,451,076	2B: FIB-4 + VCTE	4,622,691,788	24,289,461	7,396,304,441	38,863,124	8,783,114,799	46,149,978
6A: FIB-4 + ELF + Hep + SEM	94,004,724,083	25,171,599	150,407,509,346	40,274,545	178,608,983,956	47,826,040	3B: FIB-4 + VCTE + Hep + ILI	59,614,845,848	24,974,249	95,383,722,163	39,958,786	113,268,212,309	47,451,076
5A: FIB-4 + ELF + Hep + ILI + RES	659,398,534,648	25,236,693	1,055,037,310,410	40,378,695	1,252,857,273,336	47,949,719	6B: FIB-4 + VCTE + Hep + SEM	96,872,175,606	25,171,599	154,995,430,281	40,274,545	184,057,142,099	47,826,040
1: FIB-4 Only	3,770,428,157	24,045,560	6,032,683,078	38,472,884	7,163,813,827	45,686,567	5B: FIB-4 + VCTE + Hep + ILI + RES	662,244,533,464	25,236,693	1,059,590,907,026	40,378,695	1,258,264,671,334	47,949,719
7A: FIB-4 + ELF + Hep + ILI + SEM	140,187,409,813	24,975,840	224,299,782,348	39,961,331	266,356,090,870	47,454,099	7B: FIB-4 + VCTE + Hep + ILI + SEM	143,023,358,205	24,975,840	228,837,298,293	39,961,331	271,744,393,063	47,454,099
4A: FIB-4 + ELF + Hep + RES	621,307,840,824	25,039,860	994,092,220,222	40,063,763	1,180,484,951,747	47,575,737	4B: FIB-4 + VCTE + Hep + RES	614,995,248,359	25,039,860	983,992,075,581	40,063,763	1,168,491,025,514	47,575,737

Tanzania - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	1,084,173,598	14,630,993	1,734,677,074	23,409,580	2,059,930,287	27,798,893	0: Standard of care	1,177,118,121	14,630,993	1,883,388,251	23,409,580	2,236,524,918	27,798,893
1: FIB-4 Only	1,193,268,327	14,706,334	1,909,228,571	23,530,126	2,267,210,317	27,942,041	1: FIB-4 Only	1,288,905,533	14,706,334	2,062,248,041	23,530,126	2,448,921,049	27,942,041
2A: FIB-4 + ELF	1,474,380,516	14,844,493	2,359,007,897	23,751,180	2,801,323,594	28,204,544	2B: FIB-4 + VCTE	1,782,652,641	14,844,493	2,852,243,102	23,751,180	3,387,040,759	28,204,544
3A: FIB-4 + ELF + Hep + ILI	11,739,790,542	15,225,413	18,783,657,469	24,360,652	22,305,606,907	28,928,292	3B: FIB-4 + VCTE + Hep + ILI	34,552,029,723	15,225,413	55,283,225,779	24,360,652	65,648,870,825	28,928,292
6A: FIB-4 + ELF + Hep + SEM	156,282,044,360	15,326,000	250,051,172,479	24,521,590	296,935,949,203	29,119,406	6B: FIB-4 + VCTE + Hep + SEM	157,996,840,632	15,326,000	252,794,845,434	24,521,590	300,194,062,833	29,119,406
5A: FIB-4 + ELF + Hep + ILI + RES	399,744,375,196	15,385,195	639,590,748,372	24,616,302	759,514,478,923	29,231,876	5B: FIB-4 + VCTE + Hep + ILI + RES	401,446,342,299	15,385,195	642,313,894,664	24,616,302	762,748,217,126	29,231,876
7A: FIB-4 + ELF + Hep + ILI + SEM	183,822,883,077	15,235,025	294,116,497,068	24,376,031	349,263,554,205	28,946,554	7B: FIB-4 + VCTE + Hep + ILI + SEM	185,518,839,816	15,235,025	296,830,026,781	24,376,031	352,485,872,713	28,946,554
4A: FIB-4 + ELF + Hep + RES	371,597,345,759	15,265,359	594,555,519,014	24,424,564	706,035,111,302	29,004,188	4B: FIB-4 + VCTE + Hep + RES	373,299,312,862	15,265,359	597,278,665,306	24,424,564	709,268,849,505	29,004,188

Abbreviations: AFR, World Health Organization African Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 19. Total costs and QALYs in AMR for both the ELF and VCTE arms

Brazil - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	10,598,807,454	149,768,289	16,958,091,155	239,629,252	20,137,734,292	284,559,752	0: Standard of care	10,003,124,854	149,768,289	16,004,999,038	239,629,252	19,005,937,345	284,559,752
2A: FIB-4 + ELF	11,588,310,758	153,641,593	18,541,296,369	245,826,538	22,017,790,581	291,919,029	1: FIB-4 Only	10,433,383,551	151,110,716	16,693,412,922	241,777,134	19,823,428,874	287,110,362
3A: FIB-4 + ELF + Hep + ILI	345,167,317,341	160,883,673	552,267,682,598	257,413,865	655,817,907,139	305,678,981	2B: FIB-4 + VCTE	11,315,186,784	153,641,593	18,104,298,030	245,826,538	21,498,855,027	291,919,029
6A: FIB-4 + ELF + Hep + SEM	2,523,969,539,738	163,051,887	4,038,351,079,692	260,883,007	4,795,542,156,150	309,798,587	3B: FIB-4 + VCTE + Hep + ILI	346,505,819,548	160,883,673	554,409,286,032	257,413,865	658,361,061,349	305,678,981
5A: FIB-4 + ELF + Hep + ILI + RES	4,595,330,919,358	163,426,337	7,352,529,136,171	261,482,127	8,731,128,802,580	310,510,042	6B: FIB-4 + VCTE + Hep + SEM	2,525,265,576,822	163,051,887	4,040,424,738,932	260,883,007	4,798,004,626,625	309,798,587
1: FIB-4 Only	11,046,484,838	151,110,716	17,674,374,937	241,777,134	20,988,321,327	287,110,362	5B: FIB-4 + VCTE + Hep + ILI + RES	4,596,669,421,565	163,426,337	7,354,670,739,605	261,482,127	8,733,671,956,789	310,510,042
7A: FIB-4 + ELF + Hep + ILI + SEM	2,828,824,568,544	160,749,708	4,526,119,103,571	257,199,520	5,374,766,714,583	305,424,446	7B: FIB-4 + VCTE + Hep + ILI + SEM	2,830,183,412,835	160,749,708	4,528,293,254,338	257,199,520	5,377,348,518,753	305,424,446
4A: FIB-4 + ELF + Hep + RES	4,269,271,136,159	161,519,339	6,830,833,506,810	258,430,931	8,111,615,210,544	306,886,746	4B: FIB-4 + VCTE + Hep + RES	4,270,609,638,367	161,519,339	6,832,975,110,244	258,430,931	8,114,158,364,754	306,886,746

Chile - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	1,421,735,358	6,799,849	2,274,776,650	10,879,758	2,701,297,295	12,919,713	0: Standard of care	1,530,590,895	6,799,849	2,448,945,515	10,879,758	2,908,122,824	12,919,713
2A: FIB-4 + ELF	1,479,114,529	6,975,649	2,366,583,326	11,161,039	2,810,317,724	13,253,734	1: FIB-4 Only	1,560,593,147	6,860,781	2,496,949,118	10,977,249	2,965,127,104	13,035,484
6A: FIB-4 + ELF + Hep + SEM	11,593,447,580	7,402,703	18,549,516,749	11,844,325	22,027,551,333	14,065,136	2B: FIB-4 + VCTE	1,833,402,958	6,975,649	2,933,444,831	11,161,039	3,483,465,767	13,253,734
5A: FIB-4 + ELF + Hep + ILI + RES	210,159,829,444	7,419,765	336,255,738,352	11,871,624	399,303,692,806	14,097,554	6B: FIB-4 + VCTE + Hep + SEM	13,063,246,337	7,402,703	20,901,194,838	11,844,325	24,820,169,089	14,065,136
1: FIB-4 Only	1,448,554,504	6,860,781	2,317,687,284	10,977,249	2,752,253,674	13,035,484	5B: FIB-4 + VCTE + Hep + ILI + RES	211,611,864,780	7,419,765	338,578,994,968	11,871,624	402,062,560,062	14,097,554
3A: FIB-4 + ELF + Hep + ILI	17,198,648,603	7,304,326	27,517,838,685	11,686,922	32,677,433,726	13,878,220	3B: FIB-4 + VCTE + Hep + ILI	18,650,683,940	7,304,326	29,841,095,302	11,686,922	35,436,300,983	13,878,220
7A: FIB-4 + ELF + Hep + ILI + SEM	26,591,035,734	7,298,272	42,545,658,596	11,677,236	50,522,970,028	13,866,718	7B: FIB-4 + VCTE + Hep + ILI + SEM	28,034,546,163	7,298,272	44,855,275,361	11,677,236	53,265,639,960	13,866,718
4A: FIB-4 + ELF + Hep + RES	195,356,427,344	7,333,186	312,570,294,200	11,733,097	371,177,227,628	13,933,053	4B: FIB-4 + VCTE + Hep + RES	196,808,462,681	7,333,186	314,893,550,816	11,733,097	373,936,094,884	13,933,053

Abbreviations: AMR, World Health Organization Americas Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 19. Total costs and QALYs in AMR for both the ELF and VCTE arms (continued)

United States - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	32,790,643,183	81,431,259	52,465,022,917	130,290,000	62,302,220,504	154,719,389	2B: FIB-4 + VCTE	31,854,505,426	83,214,353	50,967,202,681	133,142,950	60,523,558,809	158,107,268
1: FIB-4 Only	33,024,544,010	82,057,446	52,839,264,195	131,291,898	62,746,632,063	155,909,143	6B: FIB-4 + VCTE + Hep + SEM	296,775,953,414	87,323,694	474,841,469,559	139,717,894	563,874,297,511	165,915,014
2A: FIB-4 + ELF	33,928,726,986	83,214,353	54,285,956,786	133,142,950	64,464,579,675	158,107,268	5B: FIB-4 + VCTE + Hep + ILI + RES	3,060,794,797,476	87,766,686	4,897,271,099,395	140,426,681	5,815,509,971,063	166,756,699
6A: FIB-4 + ELF + Hep + SEM	305,395,388,090	87,323,694	488,632,563,416	139,717,894	580,251,222,989	165,915,014	0: Standard of care	32,097,289,206	81,431,259	51,355,656,683	130,290,000	60,984,847,979	154,719,389
5A: FIB-4 + ELF + Hep + ILI + RES	3,069,494,936,027	87,766,686	4,911,191,319,438	140,426,681	5,832,040,233,900	166,756,699	1: FIB-4 Only	32,371,184,643	82,057,446	51,793,889,331	131,291,898	61,505,249,297	155,909,143
3A: FIB-4 + ELF + Hep + ILI	329,753,994,530	86,455,444	527,606,329,132	138,328,694	626,532,574,078	164,265,340	3B: FIB-4 + VCTE + Hep + ILI	321,053,855,979	86,455,444	513,686,109,089	138,328,694	610,002,311,240	164,265,340
7A: FIB-4 + ELF + Hep + ILI + SEM	577,537,457,542	86,502,160	924,059,823,275	138,403,439	1,097,321,142,131	164,354,099	7B: FIB-4 + VCTE + Hep + ILI + SEM	568,799,128,384	86,502,160	910,078,498,268	138,403,439	1,080,718,317,143	164,354,099
4A: FIB-4 + ELF + Hep + RES	2,801,593,523,720	86,783,255	4,482,549,110,212	138,853,191	5,323,027,563,134	164,888,180	4B: FIB-4 + VCTE + Hep + RES	2,792,893,385,169	86,783,255	4,468,628,890,169	138,853,191	5,306,497,300,296	164,888,180

Abbreviations: AMR, World Health Organization Americas Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 20. Total costs and QALYs in SEAR for both the ELF and VCTE arms

Saudi Arabia - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
2A: FIB-4 + ELF	10,303,183,509	11,205,078	16,485,092,894	17,928,124	19,576,056,594	21,289,657	2B: FIB-4 + VCTE	10,008,535,919	11,205,078	16,013,656,770	17,928,124	19,016,225,946	21,289,657
6A: FIB-4 + ELF + Hep + SEM	42,859,156,723	11,758,414	68,574,647,760	18,813,461	81,432,430,751	22,340,995	6B: FIB-4 + VCTE + Hep + SEM	41,636,779,517	11,758,414	66,618,844,315	18,813,461	79,109,913,118	22,340,995
5A: FIB-4 + ELF + Hep + ILI + RES	331,506,802,964	11,818,064	530,410,861,554	18,908,902	629,863,180,698	22,454,331	5B: FIB-4 + VCTE + Hep + ILI + RES	330,299,200,472	11,818,064	528,478,697,652	18,908,902	627,568,735,035	22,454,331
3A: FIB-4 + ELF + Hep + ILI	36,374,918,424	11,641,501	58,199,866,934	18,626,401	69,112,372,993	22,118,861	3B: FIB-4 + VCTE + Hep + ILI	35,167,315,932	11,641,501	56,267,703,032	18,626,401	66,817,927,329	22,118,861
0: Standard of care	10,543,537,472	10,964,979	16,869,659,218	17,543,965	20,032,729,310	20,833,468	0: Standard of care	10,453,006,523	10,964,979	16,724,809,705	17,543,965	19,860,720,436	20,833,468
1: FIB-4 Only	10,989,028,527	11,049,297	17,582,444,874	17,678,874	20,879,162,656	20,993,672	1: FIB-4 Only	10,895,850,311	11,049,297	17,433,359,735	17,678,874	20,702,123,974	20,993,672
7A: FIB-4 + ELF + Hep + ILI + SEM	67,521,974,883	11,647,792	108,035,155,090	18,636,466	128,291,804,230	22,130,813	7B: FIB-4 + VCTE + Hep + ILI + SEM	66,321,462,230	11,647,792	106,114,334,929	18,636,466	126,010,829,265	22,130,813
4A: FIB-4 + ELF + Hep + RES	308,865,172,968	11,685,642	494,184,255,144	18,697,026	586,844,066,285	22,202,729	4B: FIB-4 + VCTE + Hep + RES	307,657,568,926	11,685,642	492,252,088,762	18,697,026	584,549,617,676	22,202,729

Abbreviations: SEAR, World Health Organization South-East Asian Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 21. Total costs and QALYs in EUR for both the ELF and VCTE arms

Germany - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
2A: FIB-4 + ELF	2,038,302,220	14,255,138	3,261,282,789	22,808,215	3,872,773,482	27,084,756	1: FIB-4 Only	2,276,654,287	14,138,342	3,642,646,008	22,621,341	4,325,642,325	26,862,844
6A: FIB-4 + ELF + Hep + SEM	17,157,592,927	14,545,317	27,452,142,263	23,272,501	32,599,420,371	27,636,096	2B: FIB-4 + VCTE	2,683,239,569	14,255,138	4,293,182,306	22,808,215	5,098,154,213	27,084,756
7A: FIB-4 + ELF + Hep + ILI + SEM	47,611,180,994	14,604,051	76,177,871,776	23,366,476	90,461,226,710	27,747,691	6B: FIB-4 + VCTE + Hep + SEM	20,590,960,010	14,545,317	32,945,528,313	23,272,501	39,122,816,591	27,636,096
5A: FIB-4 + ELF + Hep + ILI + RES	691,136,650,693	14,748,056	1,105,818,382,517	23,596,884	1,313,159,386,960	28,021,301	7B: FIB-4 + VCTE + Hep + ILI + SEM	51,024,795,577	14,604,051	81,639,653,831	23,366,476	96,947,093,186	27,747,691
3A: FIB-4 + ELF + Hep + ILI	34,086,635,770	14,566,322	54,538,604,478	23,306,110	64,764,595,664	27,676,007	5B: FIB-4 + VCTE + Hep + ILI + RES	694,563,161,117	14,748,056	1,111,300,797,913	23,596,884	1,319,669,755,530	28,021,301
4A: FIB-4 + ELF + Hep + RES	660,902,413,857	14,611,756	1,057,443,614,891	23,378,803	1,255,714,347,880	27,762,330	3B: FIB-4 + VCTE + Hep + ILI	37,513,146,194	14,566,322	60,021,019,875	23,306,110	71,274,964,234	27,676,007
1: FIB-4 Only	2,085,468,163	14,138,342	3,336,748,280	22,621,341	3,962,388,757	26,862,844	4B: FIB-4 + VCTE + Hep + RES	664,328,924,281	14,611,756	1,062,926,030,288	23,378,803	1,262,224,716,449	27,762,330
0: Standard of care	2,095,854,787	14,071,909	3,353,366,875	22,515,049	3,982,123,339	26,736,622	0: Standard of care	2,281,113,801	14,071,909	3,649,781,227	22,515,049	4,334,115,398	26,736,622

Italy - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	1,993,747,189	15,744,403	3,189,996,226	25,191,051	3,788,119,710	29,914,367	0: Standard of care	1,987,745,170	15,744,403	3,180,392,993	25,191,051	3,776,715,874	29,914,367
1: FIB-4 Only	2,099,090,623	15,870,084	3,358,545,759	25,392,140	3,988,272,238	30,153,159	2B: FIB-4 + VCTE	2,299,144,708	16,118,474	3,678,632,367	25,789,565	4,368,375,004	30,625,102
2A: FIB-4 + ELF	2,319,203,661	16,118,474	3,710,726,700	25,789,565	4,406,487,016	30,625,102	6B: FIB-4 + VCTE + Hep + SEM	16,513,717,798	17,109,842	26,421,954,471	27,375,753	31,376,064,244	32,508,700
6A: FIB-4 + ELF + Hep + SEM	16,625,835,215	17,109,842	26,601,342,379	27,375,753	31,589,087,339	32,508,700	5B: FIB-4 + VCTE + Hep + ILI + RES	515,237,727,672	17,164,099	824,380,551,316	27,462,564	978,951,695,937	32,611,788
5A: FIB-4 + ELF + Hep + ILI + RES	515,348,603,538	17,164,099	824,557,952,741	27,462,564	979,162,360,085	32,611,788	1: FIB-4 Only	2,092,851,845	15,870,084	3,348,563,711	25,392,140	3,976,418,559	30,153,159
3A: FIB-4 + ELF + Hep + ILI	41,995,287,194	16,909,958	67,192,474,755	27,055,939	79,791,046,757	32,128,920	3B: FIB-4 + VCTE + Hep + ILI	41,884,411,328	16,909,958	67,015,073,330	27,055,939	79,580,382,610	32,128,920
7A: FIB-4 + ELF + Hep + ILI + SEM	52,979,605,638	16,868,349	84,767,388,253	26,989,365	100,661,252,085	32,049,864	7B: FIB-4 + VCTE + Hep + ILI + SEM	52,869,482,035	16,868,349	84,591,190,448	26,989,365	100,452,017,237	32,049,864
4A: FIB-4 + ELF + Hep + RES	479,034,359,157	16,973,493	766,455,148,548	27,157,595	910,165,294,819	32,249,637	4B: FIB-4 + VCTE + Hep + RES	478,923,483,291	16,973,493	766,277,747,123	27,157,595	909,954,630,672	32,249,637

Abbreviations: EUR, World Health Organization European Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 21. Total costs and QALYs in EUR for both the ELF and VCTE arms (continued)

Spain - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	2,310,647,105	7,968,534	3,697,035,973	12,749,657	4,390,230,104	15,140,217	0: Standard of care	2,307,866,719	7,968,534	3,692,587,355	12,749,657	4,384,947,371	15,140,217
2A: FIB-4 + ELF	2,759,981,267	8,093,185	4,415,970,750	12,949,098	5,243,965,130	15,377,054	2B: FIB-4 + VCTE	2,750,759,472	8,093,185	4,401,215,875	12,949,098	5,226,443,717	15,377,054
6A: FIB-4 + ELF + Hep + SEM	13,283,358,708	8,386,021	21,253,377,410	13,417,636	25,238,385,023	15,933,442	6B: FIB-4 + VCTE + Hep + SEM	13,232,061,498	8,386,021	21,171,301,860	13,417,636	25,140,920,310	15,933,442
5A: FIB-4 + ELF + Hep + ILI + RES	223,232,257,073	8,408,061	357,171,669,751	13,452,899	424,141,346,873	15,975,318	5B: FIB-4 + VCTE + Hep + ILI + RES	223,181,343,641	8,408,061	357,090,208,246	13,452,899	424,044,611,338	15,975,318
1: FIB-4 Only	2,532,498,118	8,012,143	4,051,997,652	12,819,431	4,811,747,088	15,223,073	1: FIB-4 Only	2,529,637,183	8,012,143	4,047,420,154	12,819,431	4,806,311,309	15,223,073
3A: FIB-4 + ELF + Hep + ILI	22,464,130,540	8,320,627	35,942,614,745	13,313,005	42,681,853,907	15,809,193	3B: FIB-4 + VCTE + Hep + ILI	22,413,217,108	8,320,627	35,861,153,240	13,313,005	42,585,118,372	15,809,193
7A: FIB-4 + ELF + Hep + ILI + SEM	28,897,204,021	8,321,318	46,235,533,998	13,314,111	54,904,695,205	15,810,507	7B: FIB-4 + VCTE + Hep + ILI + SEM	28,846,470,386	8,321,318	46,154,360,168	13,314,111	54,808,301,284	15,810,507
4A: FIB-4 + ELF + Hep + RES	207,829,929,554	8,342,485	332,527,941,688	13,347,979	394,876,920,554	15,850,724	4B: FIB-4 + VCTE + Hep + RES	207,779,016,121	8,342,485	332,446,480,182	13,347,979	394,780,185,019	15,850,724

Sweden - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	1,051,213,890	396,316	1,681,942,186	634,106	1,997,305,667	753,001	0: Standard of care	1,088,572,781	396,316	1,741,716,410	634,106	2,068,287,534	753,001
2A: FIB-4 + ELF	1,332,108,631	401,130	2,131,373,762	641,807	2,531,005,482	762,146	1: FIB-4 Only	1,238,124,002	398,311	1,980,998,359	637,298	2,352,434,752	756,791
3A: FIB-4 + ELF + Hep + ILI	3,323,476,053	405,228	5,317,561,564	648,364	6,314,602,211	769,932	2B: FIB-4 + VCTE	1,481,441,103	401,130	2,370,305,710	641,807	2,814,737,075	762,146
7A: FIB-4 + ELF + Hep + ILI + SEM	5,417,222,630	407,619	8,667,556,011	652,190	10,292,719,265	774,476	3B: FIB-4 + VCTE + Hep + ILI	3,697,247,460	405,228	5,915,595,801	648,364	7,024,767,627	769,932
5A: FIB-4 + ELF + Hep + ILI + RES	16,794,055,164	410,095	26,870,487,653	656,152	31,908,693,243	779,180	7B: FIB-4 + VCTE + Hep + ILI + SEM	5,790,957,924	407,619	9,265,532,468	652,190	11,002,816,066	774,476
1: FIB-4 Only	1,200,680,328	398,311	1,921,088,482	637,298	2,281,291,797	756,791	5B: FIB-4 + VCTE + Hep + ILI + RES	17,167,826,570	410,095	27,468,521,890	656,152	32,618,858,659	779,180
6A: FIB-4 + ELF + Hep + SEM	4,380,051,769	404,179	7,008,082,672	646,686	8,322,095,344	767,939	6B: FIB-4 + VCTE + Hep + SEM	4,753,974,689	404,179	7,606,359,330	646,686	9,032,548,634	767,939
4A: FIB-4 + ELF + Hep + RES	15,760,632,873	406,444	25,217,012,026	650,311	29,945,191,604	772,244	4B: FIB-4 + VCTE + Hep + RES	16,134,404,280	406,444	25,815,046,263	650,311	30,655,357,019	772,244

Abbreviations: EUR, World Health Organization European Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 22. Total costs and QALYs in EMR for both the ELF and VCTE arms

Thailand - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	2,296,536,447	22,922,780	3,674,457,912	36,676,444	4,363,417,634	43,553,266	0: Standard of care	2,303,659,447	22,922,780	3,685,854,710	36,676,444	4,376,951,328	43,553,266
2A: FIB-4 + ELF	2,869,221,162	23,215,105	4,590,753,354	37,144,164	5,451,518,188	44,108,684	2B: FIB-4 + VCTE	2,894,314,748	23,215,105	4,630,903,087	37,144,164	5,499,195,983	44,108,684
3A: FIB-4 + ELF + Hep + ILI	69,950,597,396	23,606,057	111,920,943,524	37,769,687	132,906,085,814	44,851,492	3B: FIB-4 + VCTE + Hep + ILI	70,138,924,601	23,606,057	112,222,267,018	37,769,687	133,263,907,371	44,851,492
7A: FIB-4 + ELF + Hep + ILI + SEM	136,871,984,430	23,696,045	218,995,151,002	37,913,667	260,056,674,074	45,022,468	7B: FIB-4 + VCTE + Hep + ILI + SEM	137,060,311,030	23,696,045	219,296,473,529	37,913,667	260,414,494,481	45,022,468
5A: FIB-4 + ELF + Hep + ILI + RES	668,803,036,659	23,786,966	1,070,084,740,962	38,059,142	1,270,725,298,884	45,195,219	5B: FIB-4 + VCTE + Hep + ILI + RES	668,991,363,864	23,786,966	1,070,386,064,457	38,059,142	1,271,083,120,441	45,195,219
1: FIB-4 Only	2,528,189,174	23,025,022	4,045,102,234	36,840,031	4,803,557,652	43,747,526	1: FIB-4 Only	2,535,509,872	23,025,022	4,056,815,349	36,840,031	4,817,466,972	43,747,526
6A: FIB-4 + ELF + Hep + SEM	136,874,261,503	23,562,466	218,998,794,318	37,699,941	260,061,000,510	44,768,668	6B: FIB-4 + VCTE + Hep + SEM	137,062,598,656	23,562,466	219,300,133,730	37,699,941	260,418,840,969	44,768,668
4A: FIB-4 + ELF + Hep + RES	622,860,876,592	23,651,284	996,577,292,940	37,842,051	1,183,435,227,096	44,937,423	4B: FIB-4 + VCTE + Hep + RES	623,049,203,797	23,651,284	996,878,616,435	37,842,051	1,183,793,048,653	44,937,423


Abbreviations: EMR, World Health Organization Eastern Mediterranean Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 23. Total costs and QALYs in WPR for both the ELF and VCTE arms

Japan - Main results. Total Costs and Total QALYs for all coverage levels													
Management approaches (using ELF)	50% Coverage		80% Coverage		95% Coverage		Management approaches (using VCTE)	50% Coverage		80% Coverage		95% Coverage	
	Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs		Costs (I\$)	QALYs	Costs (I\$)	QALYs	Costs (I\$)	QALYs
0: Standard of care	237,721,362,572	256,431,788	380,354,180,115	410,290,861	451,670,588,887	487,220,397	0: Standard of care	237,738,301,263	256,431,788	380,381,282,020	410,290,861	451,702,772,399	487,220,397
2A: FIB-4 + ELF	238,847,789,391	264,141,081	382,156,463,025	422,625,730	453,810,799,842	501,868,054	2B: FIB-4 + VCTE	238,916,780,855	264,141,081	382,266,849,368	422,625,730	453,941,883,624	501,868,054
6A: FIB-4 + ELF + Hep + SEM	310,638,186,549	272,170,215	497,021,098,478	435,472,344	590,212,554,442	517,123,409	6B: FIB-4 + VCTE + Hep + SEM	310,777,921,811	272,170,215	497,244,674,897	435,472,344	590,478,051,440	517,123,409
7A: FIB-4 + ELF + Hep + ILI + SEM	862,479,395,071	276,154,539	1,379,967,032,113	441,847,262	1,638,710,850,634	524,693,624	7B: FIB-4 + VCTE + Hep + ILI + SEM	862,619,109,127	276,154,539	1,380,190,574,603	441,847,262	1,638,976,307,341	524,693,624
5A: FIB-4 + ELF + Hep + ILI + RES	7,990,629,170,211	278,847,746	12,785,006,672,337	446,156,393	15,182,195,423,400	529,810,717	5B: FIB-4 + VCTE + Hep + ILI + RES	7,990,768,890,383	278,847,746	12,785,230,224,613	446,156,393	15,182,460,891,728	529,810,717
3A: FIB-4 + ELF + Hep + ILI	798,199,250,601	273,479,494	1,277,118,800,961	437,567,191	1,516,578,576,142	519,611,039	3B: FIB-4 + VCTE + Hep + ILI	798,338,970,773	273,479,494	1,277,342,353,237	437,567,191	1,516,844,044,469	519,611,039
1: FIB-4 Only	240,896,102,552	259,179,540	385,433,764,083	414,687,264	457,702,594,848	492,441,126	1: FIB-4 Only	240,913,477,252	259,179,540	385,461,563,604	414,687,264	457,735,606,779	492,441,126
4A: FIB-4 + ELF + Hep + RES	7,438,847,554,288	274,821,557	11,902,156,086,861	439,714,492	14,133,810,353,148	522,160,959	4B: FIB-4 + VCTE + Hep + RES	7,438,987,274,461	274,821,557	11,902,379,639,137	439,714,492	14,134,075,821,475	522,160,959


Abbreviations: WPR, World Health Organization Western Pacific Region; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eFigure 13. Expansion path for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)




Abbreviations: AFR, World Health Organization African Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 14. Expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)




Abbreviations: AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 14. Expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States) (continued)




Abbreviations: AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 15. Expansion path for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)




Abbreviations: EMR, World Health Organization Eastern Mediterranean Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 16. Expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)




Abbreviations: EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 16. Expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden) (Continued)




Abbreviations: EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription.

eFigure 17. Expansion path for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand) and WPR (Japan)






Abbreviations: D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEAR, World Health Organization South-East Asian Region; SEM, semaglutide prescription; WPR, World Health Organization Western Pacific Region. eFigure s1

eFigure 18. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)




eFigure 19. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)






eFigure 20. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)




eFigure 21. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)




Spain

PSA results (per 100,000 people). Number of simulations = 1000. Coverage level 0.8




Spain

PSA results (per 100,000 people). Number of simulations = 10. Coverage level 0.8




Sweden

PSA results (per 100,000 people). Number of simulations = 1000. Coverage level 0.8




Sweden

PSA results (per 100,000 people). Number of simulations = 10. Coverage level 0.8



eFigure 22. Probabilistic sensitivity analysis: expansion path for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand) and WPR (Japan)



eTable 24. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for AFR for both ELF (left column) and VCTE (right column) arms

South Africa - Main results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	301,621,428	2,085,511	ND	145	0: Standard of care	315,175,222	2,085,511	ND	151
2A: FIB-4 + ELF	358,178,793	2,118,222	ND	169	1: FIB-4 Only	342,755,835	2,096,952	ND	163
3A: FIB-4 + ELF + Hep + ILI	4,950,665,653	2,177,940	ND	2,273	2B: FIB-4 + VCTE	403,133,103	2,118,222	ND	190
6A: FIB-4 + ELF + Hep + SEM	8,197,911,057	2,195,151	ND	3,735	3B: FIB-4 + VCTE + Hep + ILI	5,198,857,916	2,177,940	ND	2,387
5A: FIB-4 + ELF + Hep + ILI + RES	57,504,456,194	2,200,827	ND	26,129	6B: FIB-4 + VCTE + Hep + SEM	8,447,974,155	2,195,151	ND	3,848
1: FIB-4 Only	328,809,376	2,096,952	ED	157	5B: FIB-4 + VCTE + Hep + ILI + RES	57,752,648,457	2,200,827	ND	26,241
7A: FIB-4 + ELF + Hep + ILI + SEM	12,225,384,715	2,178,079	D	5,613	7B: FIB-4 + VCTE + Hep + ILI + SEM	12,472,700,506	2,178,079	D	5,726
4A: FIB-4 + ELF + Hep + RES	54,182,664,411	2,183,662	D	24,813	4B: FIB-4 + VCTE + Hep + RES	53,632,159,401	2,183,662	D	24,561
Tanzania - Main results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	155,296,540	2,095,737	ND	74	0: Standard of care	168,609,872	2,095,737	ND	80
1: FIB-4 Only	170,923,221	2,106,529	ND	81	1: FIB-4 Only	184,622,251	2,106,529	ND	88
2A: FIB-4 + ELF	211,189,605	2,126,319	ND	99	2B: FIB-4 + VCTE	255,346,366	2,126,319	ND	120
3A: FIB-4 + ELF + Hep + ILI	1,681,602,337	2,180,881	ND	771	3B: FIB-4 + VCTE + Hep + ILI	4,949,217,257	2,180,881	ND	2,269
6A: FIB-4 + ELF + Hep + SEM	22,385,770,015	2,195,289	ND	10,197	6B: FIB-4 + VCTE + Hep + SEM	22,631,396,665	2,195,289	ND	10,309
5A: FIB-4 + ELF + Hep + ILI + RES	57,259,205,205	2,203,768	ND	25,982	5B: FIB-4 + VCTE + Hep + ILI + RES	57,502,994,211	2,203,768	ND	26,093
7A: FIB-4 + ELF + Hep + ILI + SEM	26,330,707,414	2,182,258	D	12,066	7B: FIB-4 + VCTE + Hep + ILI + SEM	26,573,635,497	2,182,258	D	12,177
4A: FIB-4 + ELF + Hep + RES	53,227,437,320	2,186,603	D	24,343	4B: FIB-4 + VCTE + Hep + RES	53,471,226,325	2,186,603	D	24,454

Abbreviations: ACER, average cost-effectiveness ratio; AFR, World Health Organization African Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 25. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms

Brazil - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	135,139,156	1,818,317	ND	74	0: Standard of care	127,569,197	1,818,317	ND	70
2A: FIB-4 + ELF	147,909,963	1,865,341	ND	79	1: FIB-4 Only	132,986,911	1,834,615	ND	72
3A: FIB-4 + ELF + Hep + ILI	4,410,771,439	1,953,260	ND	2,258	2B: FIB-4 + VCTE	144,494,047	1,865,341	ND	77
6A: FIB-4 + ELF + Hep + SEM	32,169,299,345	1,979,579	ND	16,251	3B: FIB-4 + VCTE + Hep + ILI	4,427,938,736	1,953,260	ND	2,267
5A: FIB-4 + ELF + Hep + ILI + RES	58,199,717,357	1,984,136	ND	29,333	6B: FIB-4 + VCTE + Hep + SEM	32,185,857,838	1,979,579	ND	16,259
1: FIB-4 Only	140,777,558	1,834,615	ED	77	5B: FIB-4 + VCTE + Hep + ILI + RES	58,216,642,840	1,984,136	ND	29,341
7A: FIB-4 + ELF + Hep + ILI + SEM	36,238,338,021	1,951,638	D	18,568	7B: FIB-4 + VCTE + Hep + ILI + SEM	36,255,827,330	1,951,638	D	18,577
4A: FIB-4 + ELF + Hep + RES	54,400,820,574	1,960,979	D	27,742	4B: FIB-4 + VCTE + Hep + RES	54,417,909,449	1,960,979	D	27,750
Chile - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	399,859,272	1,818,380	ND	220	0: Standard of care	422,938,290	1,831,143	ND	231
2A: FIB-4 + ELF	416,364,035	1,865,391	ND	223	1: FIB-4 Only	429,972,722	1,847,234	ND	233
6A: FIB-4 + ELF + Hep + SEM	3,254,446,424	1,979,579	ND	1,644	2B: FIB-4 + VCTE	508,262,538	1,877,493	ND	271
5A: FIB-4 + ELF + Hep + ILI + RES	58,626,699,915	1,984,153	ND	29,547	6B: FIB-4 + VCTE + Hep + SEM	3,768,871,340	1,989,308	ND	1,895
1: FIB-4 Only	407,172,191	1,834,674	ED	222	5B: FIB-4 + VCTE + Hep + ILI + RES	57,928,310,671	1,994,692	ND	29,041
3A: FIB-4 + ELF + Hep + ILI	4,840,618,617	1,953,278	D	2,478	3B: FIB-4 + VCTE + Hep + ILI	4,846,169,455	1,963,817	D	2,468
7A: FIB-4 + ELF + Hep + ILI + SEM	7,502,013,333	1,951,664	D	3,844	7B: FIB-4 + VCTE + Hep + ILI + SEM	7,593,408,592	1,962,574	D	3,869
4A: FIB-4 + ELF + Hep + RES	54,829,740,815	1,960,997	D	27,960	4B: FIB-4 + VCTE + Hep + RES	53,463,672,011	1,971,536	D	27,118

Abbreviations: ACER, average cost-effectiveness ratio; AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 25. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms (continued)

United States - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	812,509,496	1,917,097	ND	424	2B: FIB-4 + VCTE	776,053,620	1,971,827	ND	394
1: FIB-4 Only	817,854,496	1,931,838	ND	423	6B: FIB-4 + VCTE + Hep + SEM	7,542,763,904	2,066,204	ND	3,651
2A: FIB-4 + ELF	841,268,823	1,959,072	ND	429	5B: FIB-4 + VCTE + Hep + ILI + RES	73,767,626,272	2,077,448	ND	35,509
6A: FIB-4 + ELF + Hep + SEM	7,547,513,967	2,055,799	ND	3,671	3B: FIB-4 + VCTE + Hep + ILI	7,347,492,521	2,046,573	ED	3,590
5A: FIB-4 + ELF + Hep + ILI + RES	75,385,819,073	2,066,241	ND	36,485	0: Standard of care	780,007,830	1,930,506	D	404
3A: FIB-4 + ELF + Hep + ILI	8,170,829,714	2,035,366	D	4,014	1: FIB-4 Only	784,704,491	1,945,047	D	403
7A: FIB-4 + ELF + Hep + ILI + SEM	14,344,860,542	2,036,471	D	7,044	7B: FIB-4 + VCTE + Hep + ILI + SEM	13,563,575,156	2,048,046	D	6,623
4A: FIB-4 + ELF + Hep + RES	69,225,383,742	2,043,085	D	33,883	4B: FIB-4 + VCTE + Hep + RES	66,796,953,659	2,054,292	D	32,516

Abbreviations: ACER, average cost-effectiveness ratio; AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 26. Probabilistic sensitivity analysis results: total costs, QALYs, and ACERs for EMR for both ELF (left column) and VCTE (right column) arms

Saudi Arabia - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
2A: FIB-4 + ELF	1,897,513,142	1,959,072	ND	969	2B: FIB-4 + VCTE	1,797,584,331	1,971,827	ND	912
6A: FIB-4 + ELF + Hep + SEM	7,865,889,386	2,055,799	ND	3,826	3B: FIB-4 + VCTE + Hep + ILI	6,014,636,185	2,046,573	ND	2,939
5A: FIB-4 + ELF + Hep + ILI + RES	60,469,019,336	2,066,241	ND	29,265	6B: FIB-4 + VCTE + Hep + SEM	7,845,994,501	2,066,204	ND	3,797
3A: FIB-4 + ELF + Hep + ILI	6,692,556,879	2,035,366	ED	3,288	5B: FIB-4 + VCTE + Hep + ILI + RES	59,122,943,025	2,077,448	ND	28,459
0: Standard of care	1,941,191,929	1,917,097	D	1,013	0: Standard of care	1,869,435,826	1,930,506	D	968
1: FIB-4 Only	2,021,490,734	1,931,838	D	1,046	1: FIB-4 Only	1,942,820,447	1,945,047	D	999
7A: FIB-4 + ELF + Hep + ILI + SEM	12,452,545,686	2,036,471	D	6,115	7B: FIB-4 + VCTE + Hep + ILI + SEM	11,755,245,257	2,048,046	D	5,740
4A: FIB-4 + ELF + Hep + RES	56,678,557,929	2,043,085	D	27,742	4B: FIB-4 + VCTE + Hep + RES	54,654,562,930	2,054,292	D	26,605

Abbreviations: ACER, average cost-effectiveness ratio; EMR, World Health Organization Eastern Mediterranean Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 27. Probabilistic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms

Germany - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
2A: FIB-4 + ELF	286,366,212	1,904,530	ND	150	1: FIB-4 Only	318,578,658	1,902,367	ND	167
6A: FIB-4 + ELF + Hep + SEM	2,406,352,363	1,943,235	ND	1,238	2B: FIB-4 + VCTE	375,544,609	1,917,631	ND	196
7A: FIB-4 + ELF + Hep + ILI + SEM	6,711,145,734	1,951,107	ND	3,440	6B: FIB-4 + VCTE + Hep + SEM	2,967,877,253	1,955,050	ND	1,518
5A: FIB-4 + ELF + Hep + ILI + RES	96,325,577,091	1,970,335	ND	48,888	7B: FIB-4 + VCTE + Hep + ILI + SEM	6,904,960,643	1,963,345	ND	3,517
3A: FIB-4 + ELF + Hep + ILI	4,793,296,830	1,946,050	ED	2,463	5B: FIB-4 + VCTE + Hep + ILI + RES	94,993,055,433	1,982,299	ND	47,921
4A: FIB-4 + ELF + Hep + RES	92,675,180,067	1,952,121	ED	47,474	3B: FIB-4 + VCTE + Hep + ILI	4,865,235,960	1,958,015	ED	2,485
1: FIB-4 Only	292,623,863	1,888,941	D	155	4B: FIB-4 + VCTE + Hep + RES	90,160,719,598	1,964,086	ED	45,905
0: Standard of care	294,197,910	1,880,072	D	156	0: Standard of care	320,379,543	1,893,639	D	169
Italy - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	271,215,450	2,040,806	ND	133	0: Standard of care	271,145,792	2,055,564	ND	132
1: FIB-4 Only	285,419,828	2,057,097	ND	139	1: FIB-4 Only	283,845,747	2,071,676	ND	137
2A: FIB-4 + ELF	316,032,927	2,089,294	ND	151	2B: FIB-4 + VCTE	312,595,092	2,103,452	ND	149
6A: FIB-4 + ELF + Hep + SEM	2,262,245,961	2,217,789	ND	1,020	6B: FIB-4 + VCTE + Hep + SEM	2,307,843,929	2,229,670	ND	1,035
5A: FIB-4 + ELF + Hep + ILI + RES	69,687,846,172	2,224,834	ND	31,323	5B: FIB-4 + VCTE + Hep + ILI + RES	68,371,241,252	2,237,403	ND	30,558
3A: FIB-4 + ELF + Hep + ILI	5,729,475,385	2,191,885	D	2,614	3B: FIB-4 + VCTE + Hep + ILI	5,271,550,219	2,204,454	D	2,391
7A: FIB-4 + ELF + Hep + ILI + SEM	7,245,271,900	2,186,496	D	3,314	7B: FIB-4 + VCTE + Hep + ILI + SEM	6,942,401,369	2,199,463	D	3,156
4A: FIB-4 + ELF + Hep + RES	65,172,972,673	2,200,122	D	29,622	4B: FIB-4 + VCTE + Hep + RES	63,065,335,301	2,212,691	D	28,502

Abbreviations: ACER, average cost-effectiveness ratio; EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 27. Probabilistic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms (continued)

Spain - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	634,696,276	2,085,308	ND	304	0: Standard of care	635,006,855	2,093,606	ND	303
2A: FIB-4 + ELF	757,114,717	2,118,003	ND	357	2B: FIB-4 + VCTE	744,426,931	2,127,221	ND	350
6A: FIB-4 + ELF + Hep + SEM	3,628,613,128	2,194,893	ND	1,653	6B: FIB-4 + VCTE + Hep + SEM	3,550,848,029	2,207,457	ND	1,609
5A: FIB-4 + ELF + Hep + ILI + RES	61,319,225,780	2,200,580	ND	27,865	5B: FIB-4 + VCTE + Hep + ILI + RES	59,344,498,153	2,211,980	ND	26,829
1: FIB-4 Only	696,167,046	2,096,743	ED	332	1: FIB-4 Only	693,159,102	2,105,323	ED	329
3A: FIB-4 + ELF + Hep + ILI	6,217,324,947	2,177,693	D	2,855	3B: FIB-4 + VCTE + Hep + ILI	6,125,802,475	2,189,093	D	2,798
7A: FIB-4 + ELF + Hep + ILI + SEM	7,939,236,858	2,177,838	D	3,645	7B: FIB-4 + VCTE + Hep + ILI + SEM	8,144,645,100	2,188,719	D	3,721
4A: FIB-4 + ELF + Hep + RES	57,253,770,148	2,183,415	D	26,222	4B: FIB-4 + VCTE + Hep + RES	52,705,744,119	2,194,815	D	24,014
Sweden - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	2,002,459,280	718,434	ND	2,787	0: Standard of care	2,068,004,894	724,090	ND	2,856
2A: FIB-4 + ELF	2,541,249,651	727,161	ND	3,495	1: FIB-4 Only	2,333,819,693	727,671	ND	3,207
3A: FIB-4 + ELF + Hep + ILI	6,337,109,933	734,591	ND	8,627	2B: FIB-4 + VCTE	2,811,052,387	732,709	ND	3,837
7A: FIB-4 + ELF + Hep + ILI + SEM	10,351,566,697	738,925	ND	14,009	3B: FIB-4 + VCTE + Hep + ILI	6,643,220,157	740,061	ND	8,977
5A: FIB-4 + ELF + Hep + ILI + RES	31,764,476,473	743,413	ND	42,728	7B: FIB-4 + VCTE + Hep + ILI + SEM	10,691,179,318	744,402	ND	14,362
1: FIB-4 Only	2,285,248,019	722,050	ED	3,165	5B: FIB-4 + VCTE + Hep + ILI + RES	31,895,729,421	748,883	ND	42,591
6A: FIB-4 + ELF + Hep + SEM	8,335,629,743	732,690	D	11,377	6B: FIB-4 + VCTE + Hep + SEM	9,250,323,033	738,132	D	12,532
4A: FIB-4 + ELF + Hep + RES	29,981,333,455	736,796	D	40,691	4B: FIB-4 + VCTE + Hep + RES	29,763,630,234	742,267	D	40,098

Abbreviations: ACER, average cost-effectiveness ratio; EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 28. Probabilistic sensitivity analysis: total costs, QALYs, and ACERs for SEAR for both ELF (left column) and VCTE (right column) arms

Thailand - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	211,855,273	2,016,393	ND	105	0: Standard of care	211,495,712	2,031,850	ND	104
2A: FIB-4 + ELF	265,221,689	2,042,111	ND	130	2B: FIB-4 + VCTE	265,314,878	2,057,107	ND	129
3A: FIB-4 + ELF + Hep + ILI	6,476,743,941	2,076,505	ND	3,119	3B: FIB-4 + VCTE + Hep + ILI	5,989,038,141	2,090,795	ND	2,864
7A: FIB-4 + ELF + Hep + ILI + SEM	12,703,991,766	2,084,423	ND	6,095	7B: FIB-4 + VCTE + Hep + ILI + SEM	12,208,170,214	2,098,714	ND	5,817
5A: FIB-4 + ELF + Hep + ILI + RES	61,376,845,201	2,092,423	ND	29,333	5B: FIB-4 + VCTE + Hep + ILI + RES	60,246,753,113	2,106,712	ND	28,598
1: FIB-4 Only	233,114,891	2,025,388	ED	115	1: FIB-4 Only	231,241,216	2,040,703	ED	113
6A: FIB-4 + ELF + Hep + SEM	12,640,689,354	2,072,670	D	6,099	6B: FIB-4 + VCTE + Hep + SEM	13,028,119,686	2,086,955	D	6,243
4A: FIB-4 + ELF + Hep + RES	57,509,684,397	2,080,484	D	27,642	4B: FIB-4 + VCTE + Hep + RES	55,679,567,331	2,094,774	D	26,580
Japan - PSA results per 100,000 people. Number of simulations = 1000. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	1,514,979,179	1,551,491	ND	976	0: Standard of care	1,474,080,904	1,561,540	ND	944
2A: FIB-4 + ELF	1,522,412,971	1,598,120	ND	953	2B: FIB-4 + VCTE	1,481,897,472	1,607,303	ND	922
6A: FIB-4 + ELF + Hep + SEM	1,977,377,939	1,646,684	ND	1,201	6B: FIB-4 + VCTE + Hep + SEM	1,957,117,409	1,654,696	ND	1,183
7A: FIB-4 + ELF + Hep + ILI + SEM	5,501,964,180	1,670,784	ND	3,293	7B: FIB-4 + VCTE + Hep + ILI + SEM	5,295,780,731	1,678,806	ND	3,154
5A: FIB-4 + ELF + Hep + ILI + RES	50,425,594,926	1,687,075	ND	29,889	5B: FIB-4 + VCTE + Hep + ILI + RES	49,469,677,451	1,695,094	ND	29,184
3A: FIB-4 + ELF + Hep + ILI	5,082,807,386	1,654,604	ED	3,072	3B: FIB-4 + VCTE + Hep + ILI	4,749,308,475	1,662,623	ED	2,857
1: FIB-4 Only	1,534,853,443	1,568,111	D	979	1: FIB-4 Only	1,491,995,718	1,577,892	D	946
4A: FIB-4 + ELF + Hep + RES	47,223,546,589	1,662,721	D	28,401	4B: FIB-4 + VCTE + Hep + RES	45,709,929,242	1,670,741	D	27,359

Abbreviations: ACER, average cost-effectiveness ratio; SEAR, World Health Organization South-East Asian Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography; WPR, World Health Organization Western Pacific Region.

eTable 29. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for AFR for both ELF (left column) and VCTE (right column) arms

South Africa - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	301,621,428	2,085,511	ND	145	0: Standard of care	315,175,222	2,085,511	ND	151
2A: FIB-4 + ELF	358,178,793	2,118,222	ND	169	1: FIB-4 Only	342,755,835	2,096,952	ND	163
3A: FIB-4 + ELF + Hep + ILI	4,950,665,653	2,177,940	ND	2,273	2B: FIB-4 + VCTE	403,133,103	2,118,222	ND	190
6A: FIB-4 + ELF + Hep + SEM	8,197,903,293	2,195,332	ND	3,734	3B: FIB-4 + VCTE + Hep + ILI	5,198,857,916	2,177,940	ND	2,387
7A: FIB-4 + ELF + Hep + ILI + SEM	12,240,350,383	2,214,116	ND	5,528	6B: FIB-4 + VCTE + Hep + SEM	8,447,980,226	2,195,332	ND	3,848
5A: FIB-4 + ELF + Hep + ILI + RES	57,634,804,717	2,226,929	ND	25,881	7B: FIB-4 + VCTE + Hep + ILI + SEM	12,490,406,458	2,214,116	ND	5,641
1: FIB-4 Only	328,809,376	2,096,952	ED	157	5B: FIB-4 + VCTE + Hep + ILI + RES	57,884,867,815	2,226,929	ND	25,993
4A: FIB-4 + ELF + Hep + RES	54,182,664,411	2,183,662	D	24,813	4B: FIB-4 + VCTE + Hep + RES	53,632,159,401	2,183,662	D	24,561
Tanzania - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	155,296,540	2,095,737	ND	74	0: Standard of care	168,609,872	2,095,737	ND	80
1: FIB-4 Only	170,923,221	2,106,529	ND	81	1: FIB-4 Only	184,622,251	2,106,529	ND	88
2A: FIB-4 + ELF	211,189,605	2,126,319	ND	99	2B: FIB-4 + VCTE	255,346,366	2,126,319	ND	120
3A: FIB-4 + ELF + Hep + ILI	1,681,602,337	2,180,881	ND	771	3B: FIB-4 + VCTE + Hep + ILI	4,949,217,257	2,180,881	ND	2,269
7A: FIB-4 + ELF + Hep + ILI + SEM	26,427,997,736	2,214,267	ND	11,935	7B: FIB-4 + VCTE + Hep + ILI + SEM	26,673,617,487	2,214,267	ND	12,046
5A: FIB-4 + ELF + Hep + ILI + RES	57,407,568,070	2,227,068	ND	25,777	5B: FIB-4 + VCTE + Hep + ILI + RES	57,653,194,720	2,227,068	ND	25,887
6A: FIB-4 + ELF + Hep + SEM	22,386,177,185	2,195,448	ED	10,197	6B: FIB-4 + VCTE + Hep + SEM	22,631,817,424	2,195,448	ED	10,309
4A: FIB-4 + ELF + Hep + RES	53,227,437,320	2,186,603	D	24,343	4B: FIB-4 + VCTE + Hep + RES	53,471,226,325	2,186,603	D	24,454

Abbreviations: ACER, average cost-effectiveness ratio; AFR, World Health Organization African Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 30. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms

Brazil - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	128,699,225	1,818,607	ND	71	0: Standard of care	121,465,969	1,818,607	ND	67
2A: FIB-4 + ELF	140,714,569	1,865,640	ND	75	1: FIB-4 Only	126,690,516	1,834,908	ND	69
3A: FIB-4 + ELF + Hep + ILI	4,191,298,556	1,953,579	ND	2,145	2B: FIB-4 + VCTE	137,398,078	1,865,640	ND	74
7A: FIB-4 + ELF + Hep + ILI + SEM	34,629,965,667	2,005,457	ND	17,268	3B: FIB-4 + VCTE + Hep + ILI	4,207,551,724	1,953,579	ND	2,154
5A: FIB-4 + ELF + Hep + ILI + RES	56,115,764,224	2,022,744	ND	27,742	7B: FIB-4 + VCTE + Hep + ILI + SEM	34,645,705,169	2,005,457	ND	17,276
1: FIB-4 Only	134,135,283	1,834,908	ED	73	5B: FIB-4 + VCTE + Hep + ILI + RES	56,131,501,746	2,022,744	ND	27,750
6A: FIB-4 + ELF + Hep + SEM	30,649,312,439	1,980,182	ED	15,478	6B: FIB-4 + VCTE + Hep + SEM	30,665,046,058	1,980,182	ED	15,486
4A: FIB-4 + ELF + Hep + RES	51,840,916,127	1,961,297	D	26,432	4B: FIB-4 + VCTE + Hep + RES	51,857,169,295	1,961,297	D	26,440
Chile - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	380,253,677	1,818,670	ND	209	0: Standard of care	409,367,899	1,818,670	ND	225
2A: FIB-4 + ELF	395,600,162	1,865,689	ND	212	1: FIB-4 Only	417,392,223	1,834,967	ND	227
6A: FIB-4 + ELF + Hep + SEM	3,100,424,455	1,980,183	ND	1,566	2B: FIB-4 + VCTE	490,357,233	1,865,689	ND	263
7A: FIB-4 + ELF + Hep + ILI + SEM	7,083,455,963	2,005,458	ND	3,532	6B: FIB-4 + VCTE + Hep + SEM	3,493,568,876	1,980,183	ND	1,764
5A: FIB-4 + ELF + Hep + ILI + RES	56,478,873,800	2,022,745	ND	27,922	7B: FIB-4 + VCTE + Hep + ILI + SEM	7,476,546,391	2,005,458	ND	3,728
1: FIB-4 Only	387,426,657	1,834,967	ED	211	5B: FIB-4 + VCTE + Hep + ILI + RES	56,871,982,390	2,022,745	ND	28,116
3A: FIB-4 + ELF + Hep + ILI	4,599,906,257	1,953,596	D	2,355	3B: FIB-4 + VCTE + Hep + ILI	4,988,263,888	1,953,596	D	2,553
4A: FIB-4 + ELF + Hep + RES	52,249,526,878	1,961,315	D	26,640	4B: FIB-4 + VCTE + Hep + RES	52,637,884,510	1,961,315	D	26,838

Abbreviations: ACER, average cost-effectiveness ratio; AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 30. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for AMR for both ELF (left column) and VCTE (right column) arms (continued)

United States - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	772,102,602	1,917,415	ND	403	2B: FIB-4 + VCTE	750,059,899	1,959,401	ND	383
1: FIB-4 Only	777,610,131	1,932,160	ND	402	6B: FIB-4 + VCTE + Hep + SEM	6,987,426,090	2,056,389	ND	3,398
2A: FIB-4 + ELF	798,900,413	1,959,401	ND	408	7B: FIB-4 + VCTE + Hep + ILI + SEM	13,333,485,662	2,081,736	ND	6,405
6A: FIB-4 + ELF + Hep + SEM	7,190,368,269	2,056,389	ND	3,497	5B: FIB-4 + VCTE + Hep + ILI + RES	72,376,351,075	2,098,999	ND	34,481
7A: FIB-4 + ELF + Hep + ILI + SEM	13,536,450,106	2,081,736	ND	6,502	0: Standard of care	755,776,591	1,917,415	D	394
5A: FIB-4 + ELF + Hep + ILI + RES	72,579,307,995	2,098,999	ND	34,578	1: FIB-4 Only	762,225,850	1,932,160	D	394
3A: FIB-4 + ELF + Hep + ILI	7,764,529,526	2,035,717	D	3,814	3B: FIB-4 + VCTE + Hep + ILI	7,559,672,318	2,035,717	D	3,714
4A: FIB-4 + ELF + Hep + RES	65,967,527,291	2,043,436	D	32,283	4B: FIB-4 + VCTE + Hep + RES	65,762,670,083	2,043,436	D	32,182

Abbreviations: ACER, average cost-effectiveness ratio; AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 31. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for EMR for both ELF (left column) and VCTE (right column) arms

Saudi Arabia - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
2A: FIB-4 + ELF	1,801,689,236	1,959,401	ND	920	2B: FIB-4 + VCTE	1,750,165,026	1,959,401	ND	893
6A: FIB-4 + ELF + Hep + SEM	7,492,813,050	2,056,389	ND	3,644	6B: FIB-4 + VCTE + Hep + SEM	7,279,039,842	2,056,389	ND	3,540
7A: FIB-4 + ELF + Hep + ILI + SEM	11,478,132,841	2,081,736	ND	5,514	7B: FIB-4 + VCTE + Hep + ILI + SEM	11,264,389,263	2,081,736	ND	5,411
5A: FIB-4 + ELF + Hep + ILI + RES	58,019,579,686	2,098,999	ND	27,642	5B: FIB-4 + VCTE + Hep + ILI + RES	57,805,826,234	2,098,999	ND	27,540
3A: FIB-4 + ELF + Hep + ILI	6,360,781,494	2,035,717	ED	3,125	3B: FIB-4 + VCTE + Hep + ILI	6,149,611,383	2,035,717	ED	3,021
0: Standard of care	1,843,719,270	1,917,416	D	962	0: Standard of care	1,827,888,373	1,917,416	D	953
1: FIB-4 Only	1,921,621,060	1,932,160	D	995	1: FIB-4 Only	1,905,327,243	1,932,160	D	986
4A: FIB-4 + ELF + Hep + RES	54,010,399,514	2,043,436	D	26,431	4B: FIB-4 + VCTE + Hep + RES	53,799,229,132	2,043,436	D	26,328

Abbreviations: ACER, average cost-effectiveness ratio; EMR, World Health Organization Eastern Mediterranean Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 32. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms

Germany - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
2A: FIB-4 + ELF	272,371,576	1,904,867	ND	143	1: FIB-4 Only	304,221,773	1,889,260	ND	161
6A: FIB-4 + ELF + Hep + SEM	2,292,407,796	1,943,729	ND	1,179	2B: FIB-4 + VCTE	358,552,418	1,904,867	ND	188
7A: FIB-4 + ELF + Hep + ILI + SEM	6,335,409,641	1,962,359	ND	3,228	6B: FIB-4 + VCTE + Hep + SEM	2,751,220,729	1,943,729	ND	1,415
5A: FIB-4 + ELF + Hep + ILI + RES	92,397,617,673	1,974,924	ND	46,785	7B: FIB-4 + VCTE + Hep + ILI + SEM	6,794,187,225	1,962,359	ND	3,462
3A: FIB-4 + ELF + Hep + ILI	4,554,884,261	1,946,449	ED	2,340	5B: FIB-4 + VCTE + Hep + ILI + RES	92,856,407,147	1,974,924	ND	47,018
1: FIB-4 Only	278,674,205	1,889,260	D	148	3B: FIB-4 + VCTE + Hep + ILI	5,012,757,502	1,946,449	ED	2,575
0: Standard of care	280,062,135	1,880,383	D	149	0: Standard of care	304,817,683	1,880,383	D	162
4A: FIB-4 + ELF + Hep + RES	88,314,201,008	1,952,521	D	45,231	4B: FIB-4 + VCTE + Hep + RES	88,772,074,250	1,952,521	D	45,465
Italy - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	258,487,078	2,041,244	ND	127	0: Standard of care	257,708,923	2,041,244	ND	126
1: FIB-4 Only	272,144,736	2,057,538	ND	132	2B: FIB-4 + VCTE	298,081,523	2,089,742	ND	143
2A: FIB-4 + ELF	300,682,143	2,089,742	ND	144	6B: FIB-4 + VCTE + Hep + SEM	2,140,859,207	2,218,602	ND	965
6A: FIB-4 + ELF + Hep + SEM	2,155,396,577	2,218,602	ND	972	7B: FIB-4 + VCTE + Hep + ILI + SEM	6,874,682,633	2,245,755	ND	3,061
7A: FIB-4 + ELF + Hep + ILI + SEM	6,889,217,794	2,245,755	ND	3,068	5B: FIB-4 + VCTE + Hep + ILI + RES	67,139,022,777	2,264,380	ND	29,650
5A: FIB-4 + ELF + Hep + ILI + RES	67,153,558,674	2,264,380	ND	29,656	1: FIB-4 Only	271,335,885	2,057,538	ED	132
3A: FIB-4 + ELF + Hep + ILI	5,444,641,700	2,192,357	D	2,483	3B: FIB-4 + VCTE + Hep + ILI	5,430,266,769	2,192,357	D	2,477
4A: FIB-4 + ELF + Hep + RES	62,106,265,291	2,200,594	D	28,222	4B: FIB-4 + VCTE + Hep + RES	62,091,890,360	2,200,594	D	28,216

Abbreviations: ACER, average cost-effectiveness ratio; EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

eTable 32. Deterministic sensitivity analysis: Total costs, QALYs, and ACERs for EUR for both ELF (left column) and VCTE (right column) arms (continued)

Spain - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	604,843,485	2,085,873	ND	290	0: Standard of care	604,115,681	2,085,873	ND	290
2A: FIB-4 + ELF	722,462,848	2,118,502	ND	341	2B: FIB-4 + VCTE	720,048,917	2,118,502	ND	340
6A: FIB-4 + ELF + Hep + SEM	3,476,789,634	2,195,336	ND	1,584	6B: FIB-4 + VCTE + Hep + SEM	3,463,361,145	2,195,336	ND	1,578
7A: FIB-4 + ELF + Hep + ILI + SEM	7,519,695,503	2,214,122	ND	3,396	7B: FIB-4 + VCTE + Hep + ILI + SEM	7,506,268,133	2,214,122	ND	3,390
5A: FIB-4 + ELF + Hep + ILI + RES	58,538,658,967	2,226,934	ND	26,287	5B: FIB-4 + VCTE + Hep + ILI + RES	58,525,231,221	2,226,934	ND	26,281
1: FIB-4 Only	662,916,022	2,097,288	ED	316	1: FIB-4 Only	662,167,133	2,097,288	ED	316
3A: FIB-4 + ELF + Hep + ILI	5,880,293,437	2,178,038	D	2,700	3B: FIB-4 + VCTE + Hep + ILI	5,866,966,150	2,178,038	D	2,694
4A: FIB-4 + ELF + Hep + RES	54,402,326,795	2,183,760	D	24,912	4B: FIB-4 + VCTE + Hep + RES	54,388,999,507	2,183,760	D	24,906
Sweden - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	1,905,442,298	718,368	ND	2,652	0: Standard of care	1,973,159,450	718,368	ND	2,747
2A: FIB-4 + ELF	2,414,595,312	727,092	ND	3,321	1: FIB-4 Only	2,244,237,701	721,983	ND	3,108
3A: FIB-4 + ELF + Hep + ILI	6,024,170,633	734,520	ND	8,202	2B: FIB-4 + VCTE	2,685,277,054	727,092	ND	3,693
7A: FIB-4 + ELF + Hep + ILI + SEM	9,814,841,578	739,135	ND	13,279	3B: FIB-4 + VCTE + Hep + ILI	6,701,672,952	734,520	ND	9,124
5A: FIB-4 + ELF + Hep + ILI + RES	30,440,541,825	743,674	ND	40,933	7B: FIB-4 + VCTE + Hep + ILI + SEM	10,492,516,867	739,135	ND	14,196
1: FIB-4 Only	2,176,366,870	721,983	ED	3,014	5B: FIB-4 + VCTE + Hep + ILI + RES	31,118,318,777	743,674	ND	41,844
6A: FIB-4 + ELF + Hep + SEM	7,935,011,877	732,849	D	10,828	6B: FIB-4 + VCTE + Hep + SEM	8,613,001,496	732,849	D	11,753
4A: FIB-4 + ELF + Hep + RES	28,567,903,066	736,726	D	38,777	4B: FIB-4 + VCTE + Hep + RES	29,245,405,385	736,726	D	39,696

Abbreviations: ACER, average cost-effectiveness ratio; EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.


eTable 33. Deterministic sensitivity analysis: Total costs, QALYs, and ACER for WPR for both ELF (left column) and VCTE (right column) arms

Thailand - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	202,065,284	2,016,906	ND	100	0: Standard of care	202,692,015	2,016,906	ND	100
2A: FIB-4 + ELF	252,454,077	2,042,627	ND	124	2B: FIB-4 + VCTE	254,661,986	2,042,627	ND	125
3A: FIB-4 + ELF + Hep + ILI	6,154,741,137	2,077,025	ND	2,963	3B: FIB-4 + VCTE + Hep + ILI	6,171,311,477	2,077,025	ND	2,971
7A: FIB-4 + ELF + Hep + ILI + SEM	12,043,095,692	2,085,086	ND	5,776	7B: FIB-4 + VCTE + Hep + ILI + SEM	12,059,666,650	2,085,086	ND	5,784
5A: FIB-4 + ELF + Hep + ILI + RES	58,847,020,502	2,093,105	ND	28,115	5B: FIB-4 + VCTE + Hep + ILI + RES	58,863,591,579	2,093,105	ND	28,123
1: FIB-4 Only	222,447,706	2,025,902	ED	110	1: FIB-4 Only	223,091,832	2,025,902	ED	110
6A: FIB-4 + ELF + Hep + SEM	12,043,260,120	2,073,285	D	5,809	6B: FIB-4 + VCTE + Hep + SEM	12,059,831,834	2,073,285	D	5,817
4A: FIB-4 + ELF + Hep + RES	54,803,641,465	2,081,005	D	26,335	4B: FIB-4 + VCTE + Hep + RES	54,820,211,805	2,081,005	D	26,343

Japan - DSA results per 100,000 people. Coverage level 0.8									
Management approaches (using ELF)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000	Management approaches (using VCTE)	Costs (I\$) per 100,000	QALYs per 100,000	Status	ACER [Costs (I\$)/QALY] per 100,000
0: Standard of care	1,437,929,390	1,551,105	ND	927	0: Standard of care	1,438,031,849	1,551,105	ND	927
2A: FIB-4 + ELF	1,444,742,922	1,597,737	ND	904	2B: FIB-4 + VCTE	1,445,160,238	1,597,737	ND	905
6A: FIB-4 + ELF + Hep + SEM	1,878,750,570	1,646,442	ND	1,141	6B: FIB-4 + VCTE + Hep + SEM	1,879,595,875	1,646,442	ND	1,142
7A: FIB-4 + ELF + Hep + ILI + SEM	5,216,868,411	1,670,599	ND	3,123	7B: FIB-4 + VCTE + Hep + ILI + SEM	5,217,713,605	1,670,599	ND	3,123
5A: FIB-4 + ELF + Hep + ILI + RES	48,336,499,421	1,686,923	ND	28,654	5B: FIB-4 + VCTE + Hep + ILI + RES	48,337,344,664	1,686,923	ND	28,654
3A: FIB-4 + ELF + Hep + ILI	4,828,149,010	1,654,223	ED	2,919	3B: FIB-4 + VCTE + Hep + ILI	4,828,994,149	1,654,223	ED	2,919
1: FIB-4 Only	1,457,132,762	1,567,726	D	929	1: FIB-4 Only	1,457,237,859	1,567,726	D	930
4A: FIB-4 + ELF + Hep + RES	44,996,113,973	1,662,341	D	27,068	4B: FIB-4 + VCTE + Hep + RES	44,996,959,113	1,662,341	D	27,068


Abbreviations: ACER, average cost-effectiveness ratio; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; I\$, international dollars (for the year 2023); ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEAR, World Health Organization South-East Asian Region; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography; WPR, World Health Organization Western Pacific Region.


eFigure 23. Deterministic sensitivity analysis: expansion path (built through ICERs) for ELF (left column) and VCTE (right column) management approach for AFR (South Africa and Tanzania)



Abbreviations: AFR, World Health Organization African Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.


eFigure 24. Deterministic sensitivity analysis : expansion path (built through ICERs) for ELF (left column) and VCTE (right column) management approach for AMR (Brazil, Chile, and United States)






Abbreviations: AMR, World Health Organization Region of the Americas; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.





eFigure 25. Deterministic sensitivity analysis: expansion path (built through ICERs) for ELF (left column) and VCTE (right column) management approach for EMR (Saudi Arabia)



Abbreviations: EMR, World Health Organization Eastern Mediterranean Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetirom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.


eFigure 26. Deterministic sensitivity analysis: expansion path (built through ICERs) for ELF (left column) and VCTE (right column) management approach for EUR (Germany, Italy, Spain, and Sweden)





Abbreviations: EUR, World Health Organization European Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetrom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

Figure 27. Deterministic sensitivity analysis: expansion path (built through ICERs) for ELF (left column) and VCTE (right column) management approach for the SEAR (Thailand)



Abbreviations: SEAR, World Health Organization South-East Asian Region; D, dominated; ED, extendedly dominated; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4; Hep, hepatologist consult; ILI, intensive lifestyle intervention prescription; ND, non-dominated; QALYs, quality-adjusted life years; RES, resmetrom prescription; SEM, semaglutide prescription; VCTE, vibration-controlled transient elastography.

7. References

1. Estes, C. *et al.* Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. *J. Hepatol.* **69**, 896–904 (2018).
2. Younossi, Z. M., Paik, J. M., Henry, L., Stepanova, M. & Nader, F. Pharmaco-Economic Assessment of Screening Strategies for High-Risk MASLD in Primary Care. *Liver Int.* **45**, e16119 (2025).
3. Andraus, W., Canedo, B. F. & D'Albuquerque, L. A. C. Living donor liver transplantation in Brazil—current state. *Hepatobiliary Surg. Nutr.* **5**, 176–182 (2016).
4. Díaz, L. A. *et al.* Prioritization for liver transplantation using the MELD score in Chile: Inequities generated by MELD exceptions.: A collaboration between the Chilean Liver Transplant Programs, the Public Health Institute and the National Transplant Coordinator. *Ann. Hepatol.* **18**, 325–330 (2019).
5. Krauth, C. *et al.* Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies. *BMC Infect. Dis.* **19**, 1019 (2019).
6. Loosen, S. H. *et al.* Hospital Mortality and Current Trends in Liver Transplantation in Germany—a Systematic Analysis of Standardized Hospital Discharge Data, 2008–2017. *Dtsch. Arzteblatt Int.* **118**, 497–502 (2021).
7. Tacke, F., Kroy, D. C., Barreiros, A. P. & Neumann, U. P. Liver transplantation in Germany. *Liver Transpl.* **22**, 1136–1142 (2016).
8. Torre, E. *et al.* Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. *Clin. Outcomes Res. CEOR* **14**, 607–618 (2022).
9. Tatar, M., Keeshin, S. W., Mailliard, M. & Wilson, F. A. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. *JAMA Netw. Open* **3**, e2015756 (2020).
10. Nishio, T., Ito, T., Hata, K., Taura, K. & Hatano, E. Current status of liver transplantation for non-B non-C liver cirrhosis and hepatocellular carcinoma. *Ann. Gastroenterol. Surg.* **7**, 42–52 (2023).
11. Okushin, K. *et al.* Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). *J. Gastroenterol.* **57**, 587–597 (2022).
12. Umeshita, K. *et al.* Liver transplantation in Japan: Registry by the Japanese Liver Transplantation Society. *Hepatol. Res.* **46**, 1171–1186 (2016).
13. Estes, C. *et al.* Modelling NAFLD disease burden in four Asian regions—2019-2030. *Aliment. Pharmacol. Ther.* **51**, 801–811 (2020).
14. Turnes, J., Domínguez-Hernández, R. & Casado, M. Á. Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. *Gastroenterol. Hepatol.* **40**, 433–446 (2017).
15. Wessels, E. U. *et al.* Wits Transplant Unit Annual Report 2022: Adult and paediatric liver transplantation. *S. Afr. Med. J.* e1365–e1365 (2024) doi:10.7196/SAMJ.2024.v114i3b.1365.
16. Lladó, D. L. *et al.* REGISTRO ESPAÑOL DE TRASPLANTE HEPÁTICO.
17. Gruneau, L., Kechagias, S., Sandström, P., Ekstedt, M. & Henriksson, M. Cost-effectiveness analysis of noninvasive tests to identify advanced fibrosis in non-alcoholic fatty liver disease. *Hepatol. Commun.* **7**, e00191 (2023).

18. Gjesdal, G. *et al.* Waiting list and post-transplant outcome in Sweden after national centralization of heart transplant surgery. *J. Heart Lung Transplant.* **43**, 1318–1325 (2024).
19. Gal, P. *et al.* De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation. *Pharmacoeconomics* **41**, 1629–1639 (2023).
20. Phisalprapa, P. *et al.* Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand. *BMC Gastroenterol.* **21**, 1–10 (2021).
21. Ministério da Saúde. System for Managing the Unified Table of Procedures, Medications, and OPM of SUS (SIGTAP). Accessed January 28, 2025. Available from: <http://sigtap.datasus.gov.br/tabela-unificada/app/sec/inicio.jsp>.
22. Nauhaus B, Durkin M, Tan J, et al. Value in Health. Exploring Preferences in Health Care Decisions. Accessed January 28, 2025. 2014; Available from: [https://www.valueinhealthjournal.com/article/S1098-3015\(14\)02737-5/fulltext](https://www.valueinhealthjournal.com/article/S1098-3015(14)02737-5/fulltext).
23. Graham ID, Kothari A, McCutcheon C. Moving knowledge into action: A theoretical framework for knowledge translation in healthcare. *Implementation Science*. Accessed January 28, 2025. 2017; Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358076/>.
23. Chilean Ministry of Health. Fee schedules 2023.
24. Fondo Nacional de Salud, FONASA. Governmental Overview. Accessed January 28, 2025. Available from: <https://www.fonasa.cl>.
25. Red de Salud UC-Christus. Annual Performance Report. Accessed January 28, 2025. Available from: <https://www.ucchristus.cl>.
26. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011–2016. *JAMA*. 2020;323(24):2526–2528. doi:10.1001/jama.2020.4501.
27. Kassenärztliche bundesvereinigung, KBV. Der Einheitliche Bewertungsmaßstab (EBM). Accessed January 28, 2025. Available from: <https://ebm.kbv.de/>.
28. Schattenberg JM, Lazarus JV, Newsome PN, Serfaty L, Aghemo A, Augustin S, et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. *Liver Int.* 2021 Jun;41(6):1227-1242. doi: 10.1111/liv.14825.
29. Gemeinsamer Bundesausschuss (G-BA). Module 3C Semaglutide. Accessed January 28, 2025. 2020. Available from: https://www.g-ba.de/downloads/92-975-4104/2020-10-26_Modul3C_Semaglutid.pdf.
30. Italian Ministry of Health. National tariff lists of healthcare services (Tariffari nazionali delle prestazioni del Ministero della Salute). Accessed January 28, 2025. Available from: <https://www.salute.gov.it>.

31. Torre E, Di Matteo S, Bruno GM, Martinotti C, Valentino MC, Testino G, et al. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. *Clinicoecon Outcomes Res.* 2022 Sep 14;14:607-618. doi: 10.2147/CEOR.S371778.
32. Agenzia Italiana del Farmaco, AIFA. Lists of medicines for hospital use (Liste farmaci A-H). Accessed January 28, 2025. Available from: <https://www.aifa.gov.it/liste-farmaci-a-h>.
33. Japanese Ministry of Health, Labour and Welfare. Healthcare fee structure. Accessed January 28, 2025. Available from: <https://www.mhlw.go.jp/content/12404000/001209396.pdf>.
34. Japanese Society of Bone and Mineral Research. DPC data for orthopedic treatment. Accessed January 28, 2025. Available from: <https://bone.jp/dpc/24/060300.html>.
35. Ministry of Health, Labour and Welfare. Healthcare fee search menu. Accessed January 28, 2025. Available from: <https://shinryohoshu.mhlw.go.jp/shinryohoshu/searchMenu/doSearchResultYpNext&100>.
36. Lucina Clinic. Treatment information in English. Accessed January 28, 2025. Available from: <https://lucina-clinic.jp/treatment/english/>.
37. National Health Laboratory Services, South Africa. Blood costing price list 2023/24. Accessed January 28, 2025. Available from: <https://www.nhls.ac.za/>
38. Spanish Health Information System. Average healthcare costs. Accessed January 28, 2025. Available from: <https://www.saludinforma.es/portalsi/calidad-informacion-sanitaria/costes-medios-sanitarios>.
39. Official Gazette of Asturias. Regional pricing decree. Accessed January 28, 2025. Available from: https://sede.asturias.es/ast/bopa-disposiciones?p_p_id=pa_sede_bopa_web_portlet_SedeBopaDispositionWeb.
40. Castilla y León Transparency Portal. Public healthcare prices. Accessed January 28, 2025. Available from: <https://www.saludcastillayleon.es/transparencia/es/transparencia/informacion-datos-publicos/gestion-economica/coste-servicios/precios-publicos-actos-asistenciales-servicios-sanitarios>.
41. Official State Gazette of Spain (BOE). Pricing regulations. Accessed January 28, 2025. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2006-13728.
42. Extremadura Regional Government. Public pricing decree. Accessed January 28, 2025. Available from: <https://www.areadesaludmerida.es/wp-content/uploads/2021/01/Decreto-20-2018-Precios-Publicos.pdf>.
43. Osakidetza Basque Health Service. Tariff book 2022. Accessed January 28, 2025. Available from: https://www.osakidetza.euskadi.eus/contenidos/informacion/osk_servic_para_empresas/es_def/adjuntos/Libro_de_Tarifas_2022_CAS.pdf.
44. Iustel. Legal framework image. Accessed January 28, 2025. Available from: <https://www.iustel.com/contenidos/imagenes/029989.%20Imagen%201.pdf>.

45. Government of La Rioja. Public price decree 2023. Accessed January 28, 2025. Available from: https://noticias.juridicas.com/base_datos/CCAA/749524-orden-hap-11-2023-de-14-mar-ca-la-rioja-establece-y-regula-el-precio-publico.html.
46. Government of Catalonia. Tariff lists 2023. Accessed January 28, 2025. Available from: [https://www.ias.cat/adjunts/files/1286875\(1\).pdf](https://www.ias.cat/adjunts/files/1286875(1).pdf)
47. Serviges Kommuner och Regioner, SKR. Cost per Patient Analysis, KPP. Accessed January 28, 2025. Available from: <https://skr.se/skr/halsasjukvard/ekonomiavgifter/kostnadperpatientkpp.1076.html>.
48. Karolinska University Hospital. Medical Diagnostics Price List. Accessed January 28, 2025. Available from: <https://www.karolinska.se/ward/funktion/funktion-medicinsk-diagnostik-karolinska/wardgivare/kul/valkommen-som-labkund/ny-kund/MDK-prislistor/>.
49. Farmaceutiska Specialiteter i Sverige, FASS. Product Information Database. Accessed January 28, 2025. Available from: <https://www.fass.se/LIF/product?userType=0&nplId=20180613000032>.
50. Farmaceutiska Specialiteter i Sverige, FASS. Product Information Database. Accessed January 28, 2025. Available from: <https://www.fass.se/LIF/product?userType=0&nplId=20101223000144>.
51. Olumide AO, Shmueli A, Omotade OO, Adebayo ES, Alonge TO, Ogun GO. Economic costs of terminal care for selected non-communicable diseases from a healthcare perspective: a review of mortality records from a tertiary hospital in Nigeria. *BMJ Open*. 2021 Apr 24;11(4):e044969. doi: 47.1136/bmjopen-2020-044969.
52. BioMed Central Gastroenterology. Cost Analysis Table. Accessed January 28, 2025. Available from: <https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-021-01720-w/tables/1>.
53. Thai FDA. Drug Value Database. Accessed January 28, 2025. Available from: https://ndi.fda.moph.go.th/drug_value/index/public/0/60.
54. Kwong AJ, Kim WR, Lake JR, Schladt DP, Schnellinger EM, Gauntt K, et al. OPTN/SRTR 2022 Annual Data Report: Liver. *Am J Transplant*. 2024 Feb;24(2S1):S176-S265. doi: 10.1016/j.ajt.2024.01.014.
55. U.S. Bureau of Labor Statistics. Consumer Price Index Tables. Accessed January 28, 2025. Available from: <https://www.bls.gov/cpi/tables/>.
56. Lee DU, Hastie DJ, Lee KJ, Addonizio E, Fan GH, Chou H, Jung D, Lee K, Lominadze Z. The trends in cost associated with liver transplantation in the US: Analysis of weighted hospital data. *Liver Transpl*. 2023 Jun 1;29(6):626-643. doi: 10.1097/LVT.000000000000063.
57. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule Search - Code 99212. Accessed January 28, 2025. Available from: <https://www.cms.gov/medicare/physician-fee-schedule/search?Y=1&T=4&HT=0&CT=0&H1=99212&M=5>.

58. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule Search - Code 99204. Accessed January 28, 2025. Available from: <https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=4&HT=0&CT=0&H1=99204&M=5>.
59. Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule Search. Accessed January 28, 2025. Available from: <https://www.cms.gov/medicare/physician-fee-schedule/search?Y=0&T=4&HT=0&CT=0&H1=99204&M=5>.
60. Centers for Medicare & Medicaid Services. Clinical Laboratory Fee Schedule Data. Accessed January 28, 2025. Available from: <https://www.cms.gov/license/ama?file=/files/zip/24CLABQ2.zip>.
61. Novo Nordisk. Ozempic List Price Information. Accessed January 28, 2025. Available from: <https://www.novocare.com/diabetes/products/ozempic/explaining-list-price.html>.
62. ClearScript. Rezmidifra (Resmetirom) Information. Accessed January 28, 2025. Available from: <https://www.clearscript.org/rezdifra-resmetirom/>.
63. Barros, F. M., Cheinquer, H., Tsuchiya, C. T. & Santos, E. A. Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil. *Cost Eff. Resour. Alloc. CE* **11**, 25 (2013).
64. Torre, E. *et al.* Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. *Clin. Outcomes Res. CEOR* **14**, 607–618 (2022).
65. Phisalprapa, P. *et al.* Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. *Medicine (Baltimore)* **96**, e6585 (2017).
66. Pachanee, K., Wongphan, T. & Prakongsai, P. Economic Evaluation and Budget Impact Analysis of Liver Transplantation among Thai Adults in Universal Health Insurance Coverage in Thailand. *J. Health Sci. Thail.* 908–919 (2016).
67. World Development Indicators | DataBank. <https://databank.worldbank.org/source/world-development-indicators/Series/NY.GDP.PCAP.PP.KD>.
68. Torre E, Di Matteo S, Bruno GM, et al. Economic Burden of Non-Alcoholic Steatohepatitis (NASH) Among Diabetic Population in Italy: Analysis and Perspectives. *Clinicoecon Outcomes Res.* 2022 Sep 14;14:607-618. doi: 10.2147/CEOR.S371778. PMID: 36127889; PMCID: PMC9482784.
69. Park H, Yoon EL, Kim M, et al. Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population. *Liver Int.* 2024 Apr;44(4):944-954. doi: 10.1111/liv.15838.